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Introduction
Heart failure (HF) is a complex syndrome which is defined by symptoms of HF, typically 
breathlessness or fatigue either at rest or during exertion or ankle swelling, in combina-
tion with objective evidence of cardiac dysfunction at rest.1 The most common cause of 
HF is coronary artery disease, but other well known aetiologies are hypertension, valvular 
disease, cardiomyopathy and myocarditis. Most patients with HF suffer from a variety of 
signs and symptoms that influence their health status, quality of life and prognosis. The 
syndrome of HF is a large problem in Western societies, especially since its prevalence will 
probably increase further in the near future due to aging of the population and more suc-
cessful treatment of acute cardiac disease.2,3 Additionally, HF puts a substantial burden on 
health care facilities and costs.4 
For the diagnosis of HF a variety of diagnostic tests is available including assessment of 
clinical signs and symptoms of HF, laboratory blood tests, radiological examinations, elec-
trocardiography and echocardiography.1 In 1988 a new cardiac natriuretic peptide, B-type 
Natriuretic Peptide (BNP) was discovered,5 which in the following years was shown to have 
prognostic properties6 and later also appeared to have diagnostic properties in the emer-
gency department    7 and out-patient  settings.8 In addition, one study also reported improved 
prognosis when patients’ medication was guided by NT-proBNP compared to ‘clinical view’ 
guided treatment. Therefore, cardiologists, primary care physicians, and other clinicians be-
came enthusiastic about the role of natriuretic peptides in diagnosis, prognosis and guid-
ance of medical treatment of HF patients. The use of natriuretic peptides in the diagnosis of 
HF was included in recent guidelines, including the European Society of Cardiology1 and 
Dutch primary care guidelines.
Before explaining the potential benefits and limitations of BNP and NT-proBNP in clinical 
practice, and before outlining the aims of this thesis, an introduction to the mechanism of 
action of BNP and NT-proBNP will be given.
Differences between BNP and NT-proBNP: physiology
BNP is a hormonally active natriuretic peptide that is mainly released from the cardio-
myocytes in the left ventricular wall. In reaction to stretch and tension of the myocardial 
wall the pro hormone proBNP splits into BNP and the hormonally inactive remnant N-ter-
minal proBNP (NT-proBNP) by proteolytic cleavage (figure 1).9 This process occurs under 
influence of integrins, structures at the Z-disc of sarcomeres, that measure stretch of these 
sarcomeres10,11 after which both peptides will be secreted in equimolar amounts into the 
circulation. 
Circulating BNP acts as an antagonist of the renin angiotensine aldosterone system, and 
protects the body from plasma overload by inducing diuresis, natriuresis, vascular dilata-
tion and inhibition of the sympathetic nerves system.5  The half life of BNP is around 20 
minutes and the half life of NT-proBNP is around 120 minutes. BNP is known to be cleared 
from the blood by natriuretic peptide clearance receptors, by neuro endopeptidases and by 
the kidneys. Little is known on the exact clearance mechanism of NT-proBNP, although it 
has been suggested that the kidneys play a major role in this clearance.12 Absolute values General introduction
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of BNP are significantly lower than values of NT-proBNP, despite equimolar secretion. The 
reference ranges for BNP and NT-proBNP vary depending on the assay that is used and 
the nature of the control population. In general, the suggested normal range for circulat-
ing BNP is 0.5 – 30 pg/ml and for circulating NT-proBNP the suggested normal range is 
68 – 112 pg/ml.13  These natriuretic peptides may be beneficial in clinical practice since 
plasma levels of BNP and NT-proBNP are elevated in patients with HF and are related to the 
severity of the disease.14
BNP and NT-proBNP in clinical practice: promises
BNP and NT-proBNP plasma levels are promising tools in the daily management of sus-
pected or established HF. Most studies on the use of BNP and NT-proBNP in clinical practice 
addressed their diagnostic properties. However, an increasingly amount of evidence is avail-
able on the prognostic value of BNP and NT-proBNP and a single study provided hopeful 
results for the benefits of NT-proBNP guided medical treatment.
Diagnosis
Recent trials provided strong evidence that BNP and NT-proBNP are powerful diagnostic 
tools in exclusion and diagnosis of HF.   The Breathing Not Properly study showed, by means 
of receiver operating characteristics analyses, that a BNP value of 100 pg/ml was the opti-
mal value to differentiate patients with dyspnoea caused by HF from patients with dyspnoea 
due to pulmonary pathology at the emergency department (figure 2a).15 
Figure 1: Secretion of BNP and NT-proBNP (Courtesy from Roche Diagnostics)
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This value of 100 pg/ml also discriminated non-systolic HF (LVEF <45%) from non-
HF patients at the emergency department.16 It has also been suggested that BNP could 
be used to discriminate systolic from diastolic HF. Although non-systolic HF patients had 
significantly lower BNP plasma levels than systolic HF patients (LVEF >45%), BNP only 
had modest added value in differentiating non systolic from systolic HF. In another study, 
a BNP value of 100 pg/ml added significant value to the diagnosis of HF on top of clini-
cal judgement.17 An international pooled analysis of 1256 patients provided cut off values 
for NT-proBNP in an emergency department setting. An age independent cut point of 300 
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Figure 2: ROC curves for BNP (A) and NT-proBNP (B) in the diagnosis of heart failure at the emergency 
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pg/ml had a negative predictive value of 98%. Additionally, an optimal strategy to identify 
acute HF was to use age stratified cut off points of 450, 900 and 1800 pg/ml for ages <50, 
50-75, and >75 respectively which yielded 90% sensitivity and 84% specificity for acute 
HF (figure 2b).18,19Furthermore, BNP and NT-proBNP seem useful as diagnostic tools in 
primary care (where most patients with suspected HF are encountered and where only 
limited diagnostic tools are available) and as such are recommended in recent guidelines.1 
The added value of these natriuretic peptides on top of established diagnostic tools, including 
symptoms and signs, has not been properly studied, in particular in relevant subgroups, 
and currently large studies are underway addressing this issue. 
Discharge diagnoses have been instrumental in providing estimates and time trends in 
prevalence and incidence of HF. However, previous studies in the Netherlands, Sweden and 
in the United States showed that respectively 20%, 18% and 33% of the patients that were 
given the discharge diagnosis ‘HF’ at close examination did not have HF at all.20-22 Evidence 
is lacking on potential independent predictors of the discharge diagnosis HF, including BNP 
and/ or NT-proBNP and an easy applicable scoring rule could be helpful in this setting. 
Moreover, it is unknown whether the established BNP cut off value of 100 pg/ml can also 
be used at discharge after admission for HF. 
Prognosis
The prognostic value of BNP and NT-proBNP is well established in several groups of pa-
tients. An early study on 85 patients with chronic HF revealed that BNP is a strong inde-
pendent predictor of mortality.6 Another study confirmed these results in a larger research 
population of 452 systolic HF patients (LVEF <35%). In this study BNP was found to be a 
strong independent predictor of sudden death during a follow up period of 3 years.23 Fur-
thermore, NT-proBNP was a predictor of sudden death in this study population. A substudy 
of the COPERNICUS trial (n=1011) revealed that NT-proBNP was consistently associated 
with an increased risk for all-cause mortality and hospitalisation for HF in patients with 
severe HF (LVEF <25%).24 Another study by Gardner et al. on 142 patients with advanced 
HF also reported that NT-proBNP was an independent predictor of all cause mortality.25 
Guidance of treatment
BNP and NT-proBNP are influenced by drugs that are prescribed to HF patients like di-
uretics,26 beta blockers,27 ACE inhibitors or angiotensine II receptor blockers 28 and there-
fore these natriuretic peptides could possibly be used to guide medical treatment. A small 
study by the Australia-New Zealand Heart Failure Group including 69 patients with symp-
tomatic HF provided evidence of the possible benefit of a NT-proBNP guided approach to 
therapy. Half of the patients received therapy guided by plasma NT-proBNP, therapy in the 
remaining patients was guided by clinical monitoring at the same frequency, but with the 
physician blinded to the NT-proBNP result. Clinical monitoring was based on scores as-
signed to 10 symptoms or signs of HF used in the Framingham criteria for HF. The study 
found significantly lower mortality, fewer hospitalisations and episodes of decompensated 
HF in the NT-proBNP-guided therapy group (target 1680 pg/ml).29 
Larger studies are underway that are about to provide firmer evidence as to whether or 
not BNP and NT-proBNP can be used as a marker in the monitoring of treatment of HF 
patients.13Chapter 1
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Assay considerations
Recently, the US Food and Drug Administration (FDA) approved two rapid and fully au-
tomated assays for natriuretic peptide measurement assessing diagnosis and prognosis in 
cardiac abnormalities. These assays, the Triage® BNP meter (Biosite Incorporated, San Diego, 
CA) and the Elecsys NT-proBNP assay (Roche diagnostics, Mannheim Germany), are used 
to determine BNP and NT-proBNP levels in this thesis. BNP is stable in EDTA plasma with-
out addition of aprotinin at room temperature for at least 24 hours 30 and NT-proBNP is 
stable for at least one year when stored at -80°C in several different serum and plasma con-
ditions amongst which EDTA plasma.31 Both assays have been validated repeatedly,32-34 but 
the Elecsys NT-proBNP assay showed an approximately 2 – 3 fold better precision compared 
to the Triage BNP assay.35,36 Although there are pre-analytical and analytical differences be-
tween the Triage BNP assay and the Elecsys NT-proBNP assay, they do not seem to translate 
into clinically significant differences in their diagnostic and prognostic application.36
Before the two assays that are used for most determinations in the present study became 
available, another commercially available assay, the Shionoria BNP assay and in house de-
veloped radioimmunoassay kits for NT-proBNP were used. These systems show good per-
formance.37
Altogether, BNP and NT-proBNP are promising tools for the management of suspected 
and established HF in clinical practice, but it is time for an critical evaluation of their limi-
tations to their usefulness in daily care, especially in the typical older patient with relevant 
co-morbidity. 
Variables influencing BNP and NT-proBNP levels: 
potential limitations?
Although natriuretic peptide levels are of value in the diagnosis and prognosis of HF 
patients, several clinical conditions other than HF influence BNP and NT-proBNP plasma 
levels as well. These influences may be a disadvantage for the use of BNP and NT-proBNP in 
clinical practice of HF since it may lead to biased interpretations of the test results. 
Cardiac variables
BNP and NT-proBNP are also elevated in patients with acute coronary syndrome. After 
acute myocardial infarction, levels of BNP rise rapidly during the first 24 hours and then 
tend to stabilize,38 and in patients with a Q-wave infarction, a peak in NT-proBNP levels 
was found after 12 – 48 hours.39 In patients with unstable angina pectoris, BNP levels were 
found to be four times higher compared to patients with stable angina pectoris.40 Moreover, 
atrial fibrillation resulted in increased BNP levels in patients without, but not in patients 
with HF.41 Right ventricular failure due to acute pulmonary embolism can also be deter-
mined by BNP.42 Furthermore, hypertensive patients have higher BNP and NT-proBNP levels 
compared to non-hypertensive subjects.43 
Non-cardiac variables
A few studies in relatively small study populations without HF showed that anaemia causes 
elevated BNP levels44-46 and in a study on a small group of HF patients anaemia was also General introduction
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related to increased NT-proBNP levels.47 However, besides that these studies were limited in 
sample size, they only investigated one of the two peptides and only the effect of anaemia 
on NT-proBNP was investigated in HF patients. Furthermore, anaemia is often caused by 
renal dysfunction, but this co-morbidity has not been investigated in detail in these studies. 
Since both BNP and NT-proBNP are known to be elevated in case of renal dysfunction,48 and 
because renal function and HF are interrelated, a study investigating the effect of anaemia 
and renal function on both BNP and NT-proBNP in HF patients is needed.
An additional variable that is related to both BNP and NT-proBNP is obesity. In several 
large studies lower natriuretic peptide levels were associated with higher body mass index-
es.49-52 As far as diabetes is concerned, results are conflicting between BNP and NT-proBNP; 
BNP levels did not differ between patients with or without diabetes,53 but NT-proBNP levels 
seem to be higher in diabetic patients compared to non diabetics.54
Furthermore, ascitic cirrhosis, hyperaldosteronismus, hypercortisolismus, carcinoma, 
subarachnoid hemorrhage,9 lung cancer, tuberculosis and pulmonary embolism 7 are clini-
cal conditions with reported elevated natriuretic peptide levels.
Patient related variables
Recent studies showed that both BNP and NT-proBNP levels are influenced by biological 
variation, with the biological variation of BNP being higher compared to NT-proBNP (up 
to 44% and up to 35% respectively).55,56
Both BNP and NT-proBNP increase with advancing age and are higher in females com-
pared to males in healthy subjects.57 Nevertheless it is unknown whether there are differ-
ences in the age and gender dependency between the two peptides and only limited data 
are available on the age dependency of BNP and NT-proBNP in HF patients. Furthermore, 
before BNP and NT-proBNP were discovered, Atrial Natriuretic Peptide (ANP) and N-ter-
minal ANP (NT-ANP), natriuretic peptides that are mainly produced in the atria and with 
properties comparable to BNP and NT-proBNP, were studied. Although evidence is available 
on the superiority of BNP over ANP in the diagnosis of HF and of BNP/ NT-proBNP over 
ANP/ NT-ANP in the prognosis after myocardial infarction, it is unknown which peptide is 
influenced most by age and gender.
Previous research shows that BNP is related to maximal exercise performance.58 More-
over, the influence of moderate physical activity (75% of the maximum) on BNP levels 
was investigated in 10 healthy subjects, 10 HF patients with NYHA class I-II and in 10 HF 
patients with NYHA class III-IV. A significant increase in BNP levels was observed directly 
after exercise.59 However, it is not known whether B-type natriuretic peptide levels also 
reflect sub-maximal functional capacity during daily activities and whether they are related 
to quality of life.
Aims of this thesis
Further research is needed to study the influence of age on BNP and NT-proBNP in pa-
tients with HF since until now this relation has only been properly investigated in healthy 
subjects. Furthermore, renal dysfunction and anaemia are known to be closely related to 
cardiac dysfunction and by respectively decreased clearance and increased blood volume, Chapter 1
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these conditions may influence both BNP and NT-proBNP levels. However, these relations 
have not been investigated in a large group of HF patients. These conditions potentially 
influence (the interpretation of) BNP and NT-proBNP levels when measurement of HF se-
verity is the main goal. Insight in the relations between BNP and NT-proBNP levels and sub 
maximal functional capacity and physical dimensions of quality of life is needed as these 
measures reflect aspects that are important for HF patients in their daily life. For clinical 
practice it is useful to know whether single BNP and NT-proBNP cut off values should be 
used or whether these cut off values should be stratified according to variables that influ-
ence BNP and NT-proBNP plasma levels. 
Previous research showed that patients are often discharged with the wrong diagnosis.20-22 
Since diagnosis and medical treatment are related, it is important that patients are properly 
diagnosed before discharge in order to start the right medical treatment. As stated before, 
BNP and NT-proBNP have strong diagnostic properties in an emergency department setting 
in the differentiation between cardiac and pulmonary cause of dyspnoea, but it is unknown 
whether BNP and NT-proBNP can be used in the discharge diagnosis of patients admitted 
with suspected HF. 
Furthermore, it is unknown whether the promising cut off value for BNP that was de-
termined in an emergency department setting, is also valuable at discharge after hospital 
admission for suspected HF. 
We therefore aimed:
1. To assess the role of age, renal dysfunction, anaemia, functional capacity and quality of 
life on (the interpretation of) BNP and NT-proBNP plasma levels. This is addressed in 
the chapters 3, 4 and 5. 
2. To identify which of the readily available diagnostic tools are independent predictors of 
the discharge diagnosis HF, and to develop an easy applicable scoring rule using these 
independent predictors and BNP and/or NT-proBNP levels. This is studied in chapter 6.
3. To investigate the value of the currently available cut off value of BNP levels for exclu-
sion of HF in a setting of discharge from the hospital after admission for HF. 
  This is addressed in chapter 7.General introduction
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Abstract
Background: While there are data to support the use of comprehensive non-pharmaco-
logical intervention programs in patients with heart failure (HF), other studies have not 
confirmed these positive findings. Substantial differences in the type and intensity of dis-
ease management programs make it impossible to draw definitive conclusions about the 
effectiveness, optimal timing and frequency of interventions. 
Aims: 1. To determine the effectiveness of two interventions (basic support vs. intensive 
support) compared to ‘care as usual’ in HF patients, on time to first major event (HF read-
mission or death), quality of life and costs. 2. To investigate the role of underlying mecha-
nisms (knowledge, beliefs, self-care behaviour, compliance) on the effectiveness of the two 
interventions. 
Methods: This is a randomised controlled trial in which 1050 patients with heart failure 
will be randomised into three treatment arms: care as usual, basic education and support 
or intensive education and support. Outcomes of this study are; time to first major event 
(HF hospitalisation or death), quality of life (Minnesota Living with HF Questionnaire, 
RAND36 and Ladder of Life) and costs. Data will be collected during initial admission and 
then 1, 6, 12, and 18 months after discharge. In addition, data on knowledge, beliefs, self-
care behaviour and compliance will be collected. 
Results: The study started in January 2002 and results are expected at the end of 2005. 
Conclusions: This study will help health care providers in future to make rational and 
informed choices about which components of a HF management program should be ex-
panded and which components can possibly be deleted.
Background
In contrast to favourable trends for most cardiovascular diseases in recent years, the num-
ber of patients with chronic heart failure (CHF) is still growing. CHF presents a significant 
and growing public health problem in industrialised countries and is sometimes referred to 
as an epidemic.1 Because the incidence of CHF rises with age, its prevalence will markedly 
increase as our population ages.2,3 CHF places a significant economic burden on society, 
consuming about 1-2% of the health care budget, and a large proportion (approximately 
70%) of this is spent on hospitalisations.3 There is growing evidence that many of these 
hospitalisations  can be prevented by improved patient care.5,6 Additionally, CHF is a signifi-
cant burden to patients themselves. CHF has a high mortality rate and patients experience 
many adverse effects both from the disease and its treatment. Indeed, symptoms such as 
breathlessness, fatigue and oedema are frequently present, which can substantially affect 
quality of life.7
To improve patient outcomes, a number of heart failure management programs have been 
developed and tested over the past twenty years.8,9 In these programs, several organisational 
models have been used. Examples of these models are a heart failure clinic, a home based 
intervention and a hospital outreach program. Key components of all of these models are 
education and counselling by a heart failure nurse, accessibility of a health care provider in Design COACH study
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case of problems (mostly a nurse), optimization of medication and increased support after 
discharge. 
To address the effectiveness of heart failure management programs, a number of ran-
domised controlled studies  have been conducted, some of which have reported decreased 
readmission rates, increased time to first major event, decreased costs and an improve-
ment in quality of life.10-16 Moreover, a higher survival rate was recently reported in a ran-
domised, controlled trial of a home-based management program in Australia.17 However, 
several other studies have failed to support these positive findings, either by reporting nega-
tive or inconclusive results.18,21
Substantial differences in the type and intensity of disease management programs make 
it impossible to draw definitive conclusions about the effectiveness, optimal timing and 
frequency of interventions.
In addition, differences in national health care systems raise questions about the suit-
ability and comparability of heart failure management programs in different countries. To 
illustrate this, we have previously reported that an educational intervention with one home 
visit was not enough to significantly reduce re-hospitalization in a group of Dutch CHF 
patients.20 In contrast, Stewart and co-workers have reported a lower readmission rate in a 
CHF population as a result of a single home visit by a cardiac nurse.11,17
It is therefore a major challenge to identify, which program is most effective and the level 
of intensity required. There are currently no studies that compare the relative effectiveness 
of different programs.22 
This background was the rationale for designing the Coordinating study evaluating Out-
comes of Advising and Counselling in Heart Failure (COACH). In this multicenter ran-
domised study, advising and counselling at two different intensity levels will be compared 
to “care as usual” in order to evaluate the level of advising and counselling required. The 
rationale behind COACH is that if a basic program provides most of the beneficial effect 
(Figure 1), a much more intensive program is unnecessary, and too costly. In contrast, if the 
effect can only be gained by intensive advising and counselling (Figure 2) a basic support 
program may fail to provide that effect. This may indeed explain some of the “negative” 
studies, which may not have provided enough advising and counselling.  
In addition to the discussion on the effectiveness and intensity of interventions, it is vital 
to identify the mechanisms of action. Some authors state that education, follow up and 
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Figure 1: Expected event rates if a basic program provides most of the beneficial effectChapter 2
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availability of a health care provider in case of problems are the most important components 
of interventions. Others emphasize the importance of compliance to treatment and the early 
detection and treatment of clinical deterioration, suggesting that these were the key elements 
in the success of these interventions. Improved knowledge or self-care behaviour of patients 
are also considered as part of the underlying mechanism for better outcomes.11,13,14,17
Methods
Study hypothesis
The hypothesis of the COACH study is that advising and counselling will be beneficial 
to CHF patients, as compared to “care as usual”, in terms of prevention of CHF related 
mortality and morbidity, as well as quality of life and health care costs.
Primary objective
To determine the effectiveness of two interventions (basic support vs. intensive support) 
compared to “care as usual” in CHF patients, on time to first major event (heart failure 
readmission or death).  
Secondary objectives
-	 To determine the effectiveness of two interventions (basic support vs. intensive support) 
compared to “care as usual” in CHF patients, on quality of life and costs.
-	 To investigate the role of underlying mechanisms  (knowledge, beliefs, self-care behav-
iour, compliance) in the effectiveness of the 2 interventions.
Study design
A multicenter, randomised, controlled design will be used. The aim is to recruit 1050 
patients with heart failure, randomised into one control group ‘care as usual’ and two 
experimental groups’ basic support or intensive support.
The study has been approved by the central Ethics Committee. 
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Figure 2: Expected event rates if a significant effect can only be gained by intensive advising and 
counsellingDesign COACH study
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Study population
All patients  will be required to have a hospital admission for CHF (NYHA II-IV). In addi-
tion, patients must be at least 18 years of age,  with evidence  of structural underlying heart 
disease. Reasons for exclusion from the study are: concurrent inclusion in a study requiring 
additional visits to research health care personnel; restrictions that make the patient unable 
to fill in the data collection forms; invasive intervention within the last 6 months (PTCA, 
CABG, HTX, valve replacement) or planned during the following 3 months; ongoing evalu-
ation for Heart Transplantation; inability or unwillingness to give informed consent.
After confirmation of eligibility according to the above mentioned criteria, patients will 
be randomised to one of the three intervention strategies, i.e. “care as usual”, basic support, 
or intensive support.
Primary endpoint
The primary endpoint is the time to first event (readmission for CHF  or death). A hospi-
talisation for CHF is defined as an unplanned overnight stay in a hospital (different dates for 
admission and discharge) due to progression of CHF or directly related to CHF. 
Secondly, the proportion of ‘unfavourable days’ during the study will be analysed. A day 
is considered as ‘unfavourable’ if the patient is hospitalised or dead. 
In addition, data will be collected on the number of readmission days, number of read-
missions per patient and hospitalisations for CHF. Data will be collected by chart reviews, 
use of databases and interviews.
Table 1: Questionnaires used in the COACH-study
Assessment at Questionnaire
Quality of life  Baseline, 1, 6, 12, 18 months RAND36 
Ladder of Life 
Minnesota Living with Heart Failure 
Questionnaire
Knowledge  Baseline, 1, 6, 12, 18 months
Dutch Heart Failure Knowledge 
Questionnaire
Beliefs Baseline, 1, 6, 12, 18 months Beliefs about Compliance Scales 
Compliance Baseline, 1, 6, 12, 18 months Compliance questionnaire
Medication Monitoring system (MEMS®)
Food diary
Self-care behaviour Baseline, 1, 6, 12, 18 months
European Heart Failure self-care 
behaviour scale 
Depression  Baseline  CES-D 
Type-D Baseline Type-D 
Reason for readmission During the study Reasons for readmission interviewChapter 2
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Secondary endpoints 
The secondary endpoints are quality of life, health care costs, compliance, knowledge, 
beliefs and self-care behaviour. 
Assessment, randomisation and intervention protocol
Assessment and randomisation 
Following confirmation of suitability and informed consent, patients’ baseline character-
istics will be assessed from the medical chart, patient interview and patient questionnaires 
(Table 1). After the baseline assessment, patients will be randomised by a central randomi-
sation service on a 1:1:1 basis, to either “care-as-usual”, basic support or intensive support 
(Figure 3).
Follow-up assessments will take place 1, 6, 12 and 18 months after discharge. Data will 
be collected at the patients’ home by an independent data collector using a structured in-
terview. Additional data will be collected from the medical chart.
Treatment and care 
Two different types of interventions will be tested and compared to a control group as 
described below (Table 2). The content of the interventions is derived from interventions 
used in other countries, from interventions that are relevant and realistic in the Netherlands 
and according to the Dutch Heart Failure Guidelines. 
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Care-as-usual: Patients in the control group will receive usual treatment and care. After 
hospital discharge patients assigned to the control group will continue to receive routine 
management by the cardiologist and, subsequently, by their general practitioner. No ex-
tra follow-up by a heart failure nurse or a multidisciplinary team will be provided. Since 
counselling and advising by a heart failure nurse is not the usual care in the Netherlands, 
this control situation is (still) ethically feasible. Patients will visit the cardiologist at the 
outpatient clinic according to a defined schedule. This schedule consists of visits to the 
outpatient clinic 8 weeks after discharge, 6 months, 12 months, and every 6 months there-
after. Patients will be treated using current guidelines, receiving optimal doses of standard 
medication. 
Table 2: Treatment and care for patients in the ‘care as usual’ group (control), and intervention groups 
Care as usual Basic program Intensive program*
Hospital Visits by HF Nurse Visits by HF Nurse Multi-
disciplinary Advice
1 week
Advising
Home visit by HF nurse
2 week Advising Advising
3 week Advising
4 week Visit to HF nurse  Visit to HF nurse 
8 week Visit to cardiologist
Visit to cardiologist
Visit to HF nurse 
Visit to cardiologist
Visit to HF nurse  
3 months Visit to HF nurse  Visit to HF nurse 
4 months
 
Multidisciplinary Advice
5 months Visit to HF nurse 
6 months Visit to cardiologist
Visit to cardiologist 
Visit to HF nurse 
Visit to cardiologist 
Visit to HF nurse 
7 months  
8 months Visit to HF nurse
9 months Visit to HF nurse  Visit to HF nurse 
10 months  
11 months Home visit by HF nurse
12 months Visit to cardiologist
Visit to cardiologist 
Visit to HF nurse 
Visit to cardiologist 
Visit to HF nurse 
Multidisciplinary Advice
13 months  
14 months Visit to HF nurse 
15 months Visit to HF nurse  Visit to HF nurse 
16 months  
17 months Visit to HF nurse 
18 months Visit to cardiologist
Visit to cardiologist 
Visit to HF nurse 
Visit to cardiologist 
Visit to HF nurse 
* if needed additional visits or phone calls will be made.Chapter 2
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Intervention group 1: basic support: These patients will receive care from the cardiologist 
as described above. In addition, the following support will be provided: 
•	Patient (and family) education according to guidelines and protocol in hospital and dur-
ing visits to the outpatient clinic. Behavioural strategies will be used to improve compli-
ance. 
•	A telephone contact will be made within 2 weeks of discharge.
•	During their regular visits to the cardiologist at the outpatient clinic patients will also 
visit the heart failure nurse. In addition, there will be visits to the heart failure nurse 
after 4 weeks and then 3, 9 and 15 months after discharge. 
•	Telephone access to a heart failure nurse. Patients and their family/carers will be en-
couraged to contact the nurse if there is a change in the patients’ condition or if there 
are any problems or questions. The nurse can be contacted Monday to Friday 0900-
1700.
Intervention group 2: intensive support: In this group, the most intensive level of advising 
and counselling will be provided. This means that patients in this group will receive education 
and counselling similar to that in intervention group 1. 
The following extra support is provided: 
•		A home visit will be made within 10 days after discharge from the hospital. The home 
visit will allow the nurse to assess how the patient is coping in the home environment, 
the patients’ CHF status, the patients’ general health status, available medical support, 
health care and social support and future health care needs based upon this. An addi-
tional home visit will be made 11 months after discharge.
•		Patients in this group will be contacted each month during the course of the study by 
the heart failure nurse (and by their cardiologist during usual visits). If needed, ad-
ditional visits or telephone calls will be made.
•		In the first month telephone calls will be made weekly.
•		Telephone availability of a heart failure nurse during office hours and 24-hour coverage 
by a back up system.
•		The nurse will consult a multidisciplinary team at least once during hospital admission 
and once at follow-up to optimise her advice for each patient. 
  This multidisciplinary team will consist of a physiotherapist, dietician and social work-
er. Other health care professionals will be consulted, as required. 
In both intervention groups the heart failure nurses will use a computer program  to guide 
patient education and counselling. This program consists of an assessment form and patient 
education topics, which are specified for each patient visit (incl. home visit). Additionally 
patient progress is reported and the number of patient contacts that are initiated either by 
the health care provider or by the patients, are registered.
In the training of the HF nurses, the importance of counselling strategies is stressed and 
explained. In addition to providing information to patients, HF nurses are trained to in-
crease self-efficacy of patients. Material used in the intervention include a patient diary, 
brochures and samples of sodium restricted seasoning/spices  Design COACH study
31
Statistical issues
Analysis
All analyses will be conducting according the intention-to-treat principle. To meet the 
primary objective in the study, the primary variable ‘time to the first hospitalisation for 
heart failure or death’ will be evaluated using Kaplan-Meier survival analysis. Log-rank test-
ing will be done to compare the different treatment strategies. In addition, a Cox propor-
tional hazard model will be fitted for a multivariate analysis. A p-value below 0.05 will 
be considered as statistically significant and the incidence curves will be considered to be 
confirmed different.
Secondly, the proportion of ‘unfavourable days’ during the study will be analysed. A day 
is considered as ‘unfavourable’ if the patient was hospitalised or dead. 
Power calculation
The number of 1050 patients in the COACH study is based on the primary endpoint of 
time to major event. In previous international studies, event rates (hospital admission and/
or death) ranging from 30-54% are reported. It should be noted that several studies only 
include patients with a low ejection fraction and patients in NYHA III-IV. In patients with 
NYHA II, a lower event rate can be expected. In a Dutch intervention study, a readmission 
rate of 50% (control) versus 37% (experimental) within 9 months has been reported.21 
The effect-size of nursing interventions vary from a reduction in readmission rates of 27%, 
42% or 44%.11-13 In the current study with an 18 months follow-up period, the event rate 
(readmission or mortality) of control patients is estimated at 40% within 1 year. A 25% re-
duction of the major events in the basic follow up intervention (A+Cb) group is considered 
both realistic and clinically relevant. 
It was calculated that 698 subjects (349 in each group) will be needed to detect a 25% 
reduction in events (power of 90%, alpha of 0.05) in the basic intervention group (A+Cb). 
For the additional intervention group, another 349 patients will be included. 
Moreover, with 349 patients per group, the study has a 90% power to show that the num-
ber of ‘unfavourable days’ reduces by 50% by the intervention - from 60 days to 30 days (sd 
120) during the study period of 18 months.
Study organisation
Study centres
In order to include the 1050 patients in 18 months, 17 hospitals in the Netherlands are 
participating in this study. 
Steering Committee
Prof. dr. DJ van Veldhuisen, Chairman and Principal Investigator, dr. T. Jaarsma, Principal 
Investigator, DJA Lok (on behalf of the Working Group on Heart Failure of the NVVC), Prof. 
dr. KI Lie, Prof. dr. R Sanderman, Prof. dr. JGP Tijssen, dr. PHJM Dunselman, Prof. dr. WH 
van Gilst, dr. HJ Hillege, Prof. dr. AW Hoes, dr. JE Speksnijder and dr. MCM. Senten (both 
on behalf of the NHF)Chapter 2
32
Endpoint Committee
A panel of 2 cardiologists and an internist/geriatrician will judge whether a reported hos-
pitalisation of a study participant is related to heart failure (primary endpoint), cardiovas-
cular death or cardiovascular events. The panel will be blind as to whether the patient was 
in the control group or one of the intervention groups.
Support and monitoring
The study will be supported and monitored by the Trial Coordination Centre (dr HJ Hil-
lege MD PhD, N Veeger MSc) a contract research organization for clinical trials. Both the 
quality of the research data and of the intervention will be structurally monitored. To ad-
dress the quality of the intervention the data from the computer program -which is used 
for the education and counselling- is monitored and discussed monthly with the HF nurses 
by an on site visit of a research fellow.
Financial support
The Netherlands Heart Foundation (NHF) financially supports the study as one of their 
top down research programs (2000Z003). 
Conclusion
To obtain an insight into the optimisation of education and counselling of HF patients, 
this multi-centre randomised trial, aims to include 1050 HF patients.  Results from this 
trial, which recently started recruitment, will help health care providers in future to make 
rational and informed choices about which components of a HF management program 
should be expanded and which components can possibly be deleted. Design COACH study
33
References
1  Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, Grobbee DE. The epidemiol-
ogy of heart failure. Eur Heart J 1997;18:209-25. 
2  Bonneux L, Barendregt JJ, Meeter K, Bonsel GJ, van der Maas PJ. Estimating clinical morbidity due to 
ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health 
1994;84:20-8.
3  Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail 2001;3: 283-91.
4  Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’ than cancer? Five-year 
survival following a first admission for heart failure. Eur J Heart Fail 2001;3:315-22.
5  Vinson JM, Rich MW, Sperry JC. Early readmission of elderly patients with congestive heart failure. J Am 
Geriatr Soc 1990;38:1290-5.
6  Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with 
decompensated heart failure. Heart 1998;80:437-41.
7  Jaarsma T, Halfens R, Huijer Abu-Saad H, Dracup K, Stappers J, van Ree J. Quality of life in older pa-
tients with systolic and diastolic heart failure. Eur J Heart Fail 1999;1:151-60.
8  Rich MW. Heart failure disease management: a critical review. J Card Fail 1999;5:64-75.
9  McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease 
management programs in heart failure. Am J Med 2001;110:378-84.
10  Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary inter-
vention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 
1995;333:1190-5.
11  Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-based intervention on unplanned 
readmissions and survival among patients with chronic congestive heart failure: a randomised control-
led study. Lancet 1999;354:1077-83. 
12  Cline CMJ, Israelsson BYA, Willenheimer RB, Broms K, Erhardt LR. Cost effective management program 
for heart failure reduces hospitalization. Heart 1998;80:442-6.
13  Naylor MD, Brooten D, Campbell R, Jacobsen BS, Mezey MD, Pauly MV, Schwartz JS. Comprehen-
sive discharge planning and home follow-up of hospitalized elders: a randomized clinical trial. JAMA 
1999;281:613-20.
14  Krumholz HM, Amatruda J, Smith GL, Mattera JA, Roumanis SA, Radford MJ, Crombie P, Vaccarino 
V. Randomized trial of an education and support intervention to prevent readmission of patients with 
heart failure. J Am Coll Cardiol 2002;39:83-9.
15  McDonald K, Ledwidge M, Cahill J, Quigley P, Maurer B, Travers B, Ryder M, Kieran E, Timmons L, 
Ryan E. Heart failure management: Multidisciplinary care has intrinsic benefit above the optimization 
of medical care. J Card Fail 2002;8:142-8.
16  Kasper EK, Gerstenblith G, Hefter G, Van Anden E, Brinker JA, Thiemann DR, Terrin M, Forman S, Got-
tlieb SH. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high 
risk of hospital readmission. J Am Coll Cardiol 2002;39:471-80.Chapter 2
34
17  Stewart S, Horowitz JD. Home-based intervention in congestive heart failure: long-term implications 
on readmission and survival. Circulation 2002;105:2861-6.
18  Weinberger M, Oddone EZ, Henderson WG. Does increased access to primary care reduce hospital 
readmissions? N Engl J Med 1996;334:1441-7.
19  Ekman I, Andersson B, Ehnfors M, Matejka G, Persson B, Fagerberg B. Feasibility of a nurse-monitored, 
outpatient-care program for elderly patients with moderate-to-severe, chronic heart failure. Eur Heart J 
1998;19:1254-60.
20  Jaarsma T, Halfens R, Huijer Abu-Saad H, Dracup K, Gorgels A, van Ree J, Stappers J. Effects of ed-
ucation and support on self-care and resource utilization in patients with heart failure. Eur Heart J 
1999;20:673-82
21  Doughty RN, Wright SP, Pearl A, Walsh HJ, Muncaster S, Whalley GA, Gamble G, Sharpe N. Rand-
omized controlled trial of integrated heart failure management. Eur Heart J 2002;23:139-46. 
22.  Moser M, Mann D. Improving outcomes in heart failure: it;’s not unusual beyond usual care [editorial]. 
Circulation 2002;105;2810-12.Chapter 3
Influence of age on Natriuretic Peptides in patients with 
chronic heart failure: a comparison between 
ANP/ NT-ANP and BNP/ NT-proBNP
Jochem Hogenhuis, Adriaan A. Voors, Tiny Jaarsma, Hans L. Hillege, Frans Boomsma, 
Dirk J. van Veldhuisen.
Eur J Heart Fail 2005;7:81-7.Chapter 3
38
Abstract
Background: Natriuretic peptides are currently used in the diagnosis and follow-up of pa-
tients with Chronic Heart Failure (CHF). However, it is unknown whether there are dif-
ferent influences of age on atrial natriuretic peptide (ANP)/N-terminal-ANP (NT-ANP) or 
B-type natriuretic peptide (BNP)/N-terminal-proBNP (NT-proBNP). 
Aims: To compare the influence of age and gender on plasma levels of ANP/NT-ANP and 
BNP/NT-proBNP in CHF patients.  
Methods and Results: Natriuretic peptides were measured in 311 CHF patients (68 ± 8 
years, 76% males, left ventricular ejection fraction (LVEF) 0.23 ± 0.08). All natriuretic 
peptides were significantly related to age (p<0.05) on multivariate regression analysis, with 
partial correlation coefficients of 0.18, 0.29, 0.28 and 0.25 for ANP, NT-ANP, BNP and NT-
proBNP respectively. The relative increase of both BNP/NT-proBNP were more pronounced 
than of ANP/NT-ANP (p<0.01). Furthermore, the relative increase of BNP with age was 
markedly larger than of NT-proBNP (p<0.01). Levels of all natriuretic peptides were also 
significantly related to cardiothoracic ratio, renal function and LVEF. 
Conclusion: In patients with CHF, BNP/NT-proBNP were more related to age than ANP/
NT-ANP, and BNP was more related to age than NT-proBNP. However, in these CHF patients 
the influence of age on the levels of all natriuretic peptides was modest, and comparable to 
several other factors. 
Introduction
Plasma natriuretic peptides have been shown to be of additional value in the diagnosis1-4 
and prognosis5 of Chronic Heart Failure (CHF) patients. Research initially focussed on the 
Atrial Natriuretic Peptides (ANP) and N-terminal ANP [NT-ANP]), which are primarily 
secreted in the atria. In recent years, peptides secreted in the ventricles (B-type Natriuretic 
Peptide [BNP], and N-terminal proBNP [NT-proBNP]) have been increasingly studied. In a 
comparative study, the diagnostic value of BNP appeared to be superior to ANP, especially 
with regard to the positive predictive value (BNP 70%, ANP 55%).6 Furthermore BNP and 
NT-proBNP are better predictors of prognosis after myocardial infarction than ANP and 
NT-ANP. 7 However, plasma levels of natriuretic peptides are influenced by age and gen-
der in healthy subjects.8-10 Although natriuretic peptides are largely used in CHF patients, 
only limited data about the influence of age11,12 and gender13 on natriuretic peptides in 
CHF patients are available. Despite the prognostic and diagnostic superiority of BNP, direct 
comparative studies on the influence of age on BNP/NT-proBNP and ANP/NT-ANP in CHF 
patients are lacking. We therefore compared the effects of age and gender on ANP/NT-ANP 
and BNP/NT-proBNP in a large group of CHF patients. 
Methods
Study sample 
The present analyses used the baseline data of patients included in the Netherlands in the 
Prime-II study. Prime-II was designed to examine the effect of oral ibopamine against pla-Age, gender and natriuretic peptides
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cebo, on all cause mortality in patients with moderate to severe CHF. 14 Systolic dysfunction 
was an inclusion criterion of the Prime-II study (left ventricular ejection fraction < 35%). 
The design, and more inclusion and exclusion criteria of Prime-II were described in detail 
by Hampton et al. (1997).14
A predefined neurohormonal substudy consisted of 372 patients, with 311 patients hav-
ing complete datasets. The study was approved by each local Ethical Committee, and prior 
to the announcement of the investigation all patients provided informed written consent. 
The investigation conforms with the principles outlined in the declaration of Helsinki.
Natriuretic peptide measurement
At baseline of the Prime-II study, before the study drug ibopamine was started, blood 
was collected between 9:00 and 10:00 AM after patients had rested in supine position for 
>30 minutes. An intravenous canula was used to pour blood into chilled 10 ml tubes con-
taining EDTA (19 mg) and aprotinin (1000 kIU). The tubes were centrifuged within 30 
minutes (4° C, 10 minutes, 2000 x g) and plasma was separated and stored in polyethylene 
tubes at -70°C. The plasma natriuretic peptide samples were transported (on dry ice) to the 
Core Laboratory at the University Hospital Dijkzigt, Rotterdam, the Netherlands, where all 
measurements were executed. Measurement of ANP (normal value:15-35 pmol.l-1) was 
performed after SepPak extraction, with commercially available radioimmunoassay kits 
from the Nichols Institute, Wijchen, The Netherlands, as previously described.15-17 Plasma 
NT-ANP (normal value: 150-500 pmol.l-1) was determined using a commercially available 
radioimmunoassay kit (Biotop, Oulu, Finland).18 NT-proBNP was measured using a radio-
immunoassay kit with reagents including antibody, standards, and radiolabel. The assay uses 
50 µl of unextracted plasma and has a standard range of 60- 1000 pmol.l-1. All samples 
giving results of >900 pmol.l-1 were re-analysed in appropriate dilutions with physiologi-
cal salt. In 12 consecutive assays, variability was 14, 11, 4 and 4 % at concentrations of 131, 
199, 293 and 901 pmol.l-1, respectively. BNP was determined by a commercially available 
immunoradiometric assay (Shionoria, Osaka, Japan).
Statistical analyses 
To investigate the relation between natriuretic peptides and other patient characteristics 
Pearson and Spearman correlation coefficients were calculated, when appropriate. For all 
natriuretic peptides, the following predictor variables were used in univariate analyses: 
age, gender, NYHA class, the existence of coronary artery disease, dilated cardiomyopathy 
or hypertension, systolic and diastolic blood pressure, heart rate, left ventricular ejection 
fraction, cardio-thoracic ratio, sinus rhythm or atrial fibrillation, renal function and the 
medication that was taken by the patient (β-blockers, ACE inhibitors, diuretics, digoxin and 
anti-arrhythmics). A multivariate regression analyses was performed to study the relation 
between natriuretic peptides on the one hand and age and gender on the other. Because the 
plasma natriuretic peptides had a skewed distribution, the natural logarithm was used to 
get an optimal residual analysis. A p-value < 0.15 was required to enter a variable into the 
multivariate model, and a p-value > 0.05 was needed to remove a variable from the model. 
Partial correlation coefficients of the plasma level of ANP/NT-ANP and BNP/NT-proBNP 
were calculated with correction for the predictors that were entered in the multivariate  re-
gression model.Chapter 3
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Age was divided into quartiles, using the first quartile as the reference group. In all quar-
tiles the relative differences between lnANP and lnBNP, lnNT-ANP and lnNT-proBNP, lnANP 
and lnNT-ANP and lnBNP and lnNT-proBNP were investigated with paired samples t-tests.
Outcomes were considered significant when p < 0.05. Results were presented as means 
± standard deviations except when stated otherwise.
Table 1: Characteristics of study population divided in age quartiles.
Total
(n=311)
Q1: 38-62 
(n=76)
Q2: 63-69 
(n=77)
Q3: 70-73 
(n=67)
Q4: 74-80 
(n=91)
Age (years) 68 ± 8 57 ± 5             66 ± 2                     71 ± 1                   76 ± 2
Gender (%men) 76% 83% 78% 73% 71%
NYHA
III 68% 78% 68% 72% 63%
III/IV 29% 21% 29% 28% 33%
IV                               3%                   1%                             3%                       0%                   4%
Aetiology
Coronary artery disease 76% 68% 83% 72% 78%
Dilated cardiomyopathy 17% 25% 12% 18% 14%
Hypertension                     5%                     3%                   4%                   3%                   8%
Other                       3%                 4%                 1%                   7%                 0%
Heart rate (beats . min-1)                                               81 ± 15                                         81 ± 17                                 81 ± 15                                     81 ± 15                                             81 ± 14
Blood pressure 
Systolic (mmHg)                         125 ± 18                     125 ± 18                     123 ± 17                       123 ± 19                 126 ± 18
Diastolic (mmHg)                                             76 ± 10                     73 ± 8                         75 ± 9                                              75 ± 10                     76 ± 9
Serum sodium (mmol . l-1) 139 ± 3 139        ± 3 139 ± 3 139 ± 4 139 ± 3
Evidence of heart disease
LVEF               0.23 ± 0.08                         0.24 ± 0.08 0.23 ± 0.09               0.25 ± 0.06                                             0.23 ± 0.08
CT Ratio             0.56 ± 0.07                                 0.55 ± 0.05 0.55 ± 0.06           0.56 ± 0.07                                                 0.57 ± 0.07
Rhythm
Sinus rhythm 74% 87% 79% 72% 75%
Atrial fibrillation/ flutter 26% 13% 21% 28% 25%
Renal function
Creatinine (µmol/L)                                                                                 118 ± 39 107 ± 31                   114 ± 33               120 ± 32                           130 ± 50
Concomitant medication
ACE inhibitors 94% 96% 96% 97% 92%
Diuretics  99% 96% 100% 99% 99%
Digoxin 59% 50% 68% 63% 58%
Anti- arrhythmics 18% 20% 21% 13% 18%
Beta blockers 9% 12% 8% 15% 8%
CT-ratio = Cardio-thoracic ratio, LVEF = Left Ventricular Ejection Fraction, NYHA = New York Heart Associa-
tion functional class, Q = quartile.Age, gender and natriuretic peptides
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Results
Demographic and clinical characteristics of the 311 patients are presented in table 1. On 
average patients were 68 ± 8 years of age, the majority (76%) of patients of this study was 
male. A significant age difference between males and females was found (p-value < 0.05). 
The median and ranges of ANP, NT-ANP, BNP and NT-proBNP in the patient population 
were 103 (12-815) pmol.l-1, 1078 (129-4280) pmol.l-1, 60 (0.6-502) pmol.l-1 and 610 
(2-5295) pmol.l-1 respectively (table 2). 
Plasma levels of ANP/NT-ANP and BNP/NT-proBNP showed significant positive correla-
tions with age on univariate regression analyses (p-values < 0.05). Furthermore, ANP and 
NT-ANP plasma levels were significantly higher in patients with atrial fibrillation compared 
to patients with sinus rhythm (p-values < 0.05). Although a similar difference was indeed 
present, it was not statistically significant for BNP and NT-proBNP.
Multivariate predictors of natriuretic peptide plasma levels 
Left ventricular ejection fraction, cardio-thoracic ratio and renal function added significant 
value to the multivariate regression model (p-values < 0.05) for all tested natriuretic 
peptides. Gender was significantly related to ANP and NT-ANP in the multivariate model, 
while this was not the case for BNP and NT-proBNP (table 3). Use of diuretics was only 
related to ANP, and systolic blood pressure was only related to NT-ANP and NT-proBNP. The 
existence of coronary artery disease was only related to NT-proBNP.  The multivariate partial 
Table 2: Natriuretic peptide plasma levels in age quartiles (median [minimum-maximum]).
Total 
(n=311)
Q1: 38-62 
(n=76)
Q2: 63-69 
(n=77)
Q3: 70-73
 (n=67)
Q4: 74-80 
(n=91)
ANP (pmol.l-1)           103 (12-815)                         88 (12-597)                             103 (19-508)                   115 (18-720) 105 (28-815)
NT-ANP (pmol.l-1) 1078 (129-4280) 689 (129-3414) 1066 (256-3081) 1151 (239-4210) 1148 (344-3760)
BNP (pmol.l-1)           60 (0.6-502) 33 (0.6-352)                                                                     47 (3-322)           79 (1.4-502)               65 (7.6-373)
NT-proBNP (pmol.l-1)                                               610 (2-5295)                                         372      (3-2928)                                                                           527 (5-3380)                                                 711 (3-5295)                                                 715 (14-4820)
ANP = Atrial Natriuretic Peptide, BNP = B-type Natriuretic Peptide, NT-ANP = N-terminal Atrial Natriuretic 
Peptide, NT-proBNP = N-terminal pro B-type Natriuretic Peptide, Q = quartile. 
Table 3: Partial correlation coefficients for natriuretic peptides in relation with age and gender (corrected for 
CT-ratio, LVEF, plasma Creatinine, use of diuretics, SBP, CAD). 
ANP NT-ANP BNP NT-proBNP
Age                 0.18*                       0.29* 0.28* 0.25*
Gender#  -0.14† -0.18*                                                                                 -0.09 (NS)                                                                             -0.05 (NS)
* = p < 0.01, † = p < 0.05, # coding: 1 = male, 2 = female, ANP = Atrial Natriuretic Peptide, BNP = B-type 
Natriuretic Peptide, CAD = Coronary Artery Disease, CT-ratio = Cardio-thoracic ratio, LVEF = Left Ventricular 
Ejection Fraction, NT-ANP = N-terminal Atrial Natriuretic Peptide, NT-proBNP = N-terminal pro B-type Na-
triuretic Peptide, SBP = Systolic Blood Pressure.Chapter 3
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correlation coefficients in relation to age were 0.18, 0.29, 0.28 and 0.25 for ANP, NT-ANP, 
BNP and NT-proBNP respectively (table 3). The interaction term between age and gender 
did not add significant value to the multivariate regression model of all tested natriuretic 
peptides.
Direct comparisons
To directly compare the age dependency between ANP/NT-ANP and BNP/NT-proBNP, 
we divided our population in quartiles. The relative increase in lnBNP was significantly 
larger than the relative increase in lnANP, and the relative increase in lnNT-proBNP was sig-
nificantly larger than the relative increase in lnNT-ANP (figure 1). In addition, we directly 
compared lnANP to lnNT-ANP and lnBNP to lnNT-proBNP. The relative increase of lnANP 
and lnNT-ANP with age was similar (figure 1). However, the relative increase of lnBNP with 
age was significantly larger than the relative increase of lnNT-proBNP with age (figure 1). 
Discussion
Plasma natriuretic peptides are of added value both in the diagnosis1-4 and prognosis5 of 
CHF. Direct comparative studies indicated both diagnostic6 and prognostic 7 superiority of 
BNP/NT-proBNP over ANP/NT-ANP. Although age-dependency of plasma levels of both 
ANP/NT-ANP and BNP/NT-proBNP has been demonstrated, direct comparative studies on 
age-dependency between ANP/NT-ANP and BNP/NT-proBNP in CHF patients were not 
available. In a large group of CHF patients, we demonstrated that BNP/NT-proBNP were 
influenced by age to a larger extend than ANP/NT-ANP. We also demonstrated that the rela-
tive increase of BNP with age was significantly larger than NT-proBNP. 
Relation ANP/NT-ANP, BNP/NT-proBNP and age in healthy adults
The relation between age and levels of natriuretic peptides is well described in healthy 
subjects.9,19 In a large group of healthy adults (n=911), Wang and co-workers calculated 
multivariate correlations between ANP/NT-ANP, BNP and age. After multivariate adjust-
ment, a 10 year increase in age was associated with a 1.4 fold increase in BNP levels and a 
1.2 fold increase in NT-ANP.10 Another large study in healthy subjects (n=216) showed a 
weak, but significant relationship between age and both ANP and BNP. 8 Raymond et al. ana-
lysed a healthy sub group (n=130) of a large sample of the general population, and found 
a strong positive relationship between NT-proBNP and age.20
Relation ANP/NT-ANP, BNP/NT-proBNP and age in CHF patients
In contrast to healthy subjects, the relation between age and natriuretic peptides is less 
well described in CHF patients. This seems contradictory, since natriuretic peptides are gen-
erally used in CHF patients. Interestingly, Dutka et al. demonstrated that although ANP levels 
increased with age in healthy subjects, in CHF patients, ANP levels appeared to decrease with 
age.11 In contrast, an increase of NT-ANP with age was demonstrated in a large sample of 
CHF patients.12 Although the multivariate correlation was only modest, NT-ANP increased 
approximately 3 fold from the age of 40- 80 years.12 Differences between these studies 
might be related to differences between ANP and NT-ANP, although in the current study, Age, gender and natriuretic peptides
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Figure 1: Comparison of lnANP vs lnBNP (A), lnNT-ANP vs lnNT-proBNP (B), lnBNP vs lnNT-proBNP (C) 
and lnANP vs lnNT-ANP (D) in their relative increase in age quartiles related to reference group 
(38-62 years). 
* = p < 0.01, † = p < 0.001
both ANP and NT-ANP increased with age, and we did not find a difference between the 
relative increase of either ANP or NT-ANP with age. To our knowledge, only one small study 
has demonstrated an age-dependency of BNP and NT-proBNP in CHF patients (n=92).21 In 
this study of Masson et al., the increase in plasma levels of BNP and NT-proBNP with age 
was similar.21 We confirmed this age dependency of both BNP and NT-proBNP in a large 
group of patients classified in NYHA functional class III/IV. However, we demonstrated 
that the relative increase of BNP with age was significantly larger than the relative increase 
of NT-proBNP with age. The difference between our study and the results by Masson et al. 
might be related to the severity of CHF (NYHA III-IV and mainly NYHA II, respectively), 
and the difference in age (68 vs. 57 years respectively), although these explanations remain 
highly speculative.
Direct comparisons between ANP/NT-ANP and BNP/NT-proBNP
Clerico et al. described the age dependency of ANP and BNP of healthy adults in the 
same paper. Although they found significant correlations with age for both peptides (ANP: Chapter 3
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r=0.350; BNP: r=0.254), no direct comparisons were performed.8 Another study reported 
on the age dependency of both BNP and NT-ANP. Again, significant increases with age were 
described in healthy subjects (BNP: 1.4 fold and NT-ANP: 1.2 fold increase per age decade), 
but no statistical comparisons between the natriuretic peptides were shown.10 
So, although age-dependency of both ANP/NT-ANP and BNP/NT-proBNP has been well 
described, to our knowledge this is the first direct comparative study. Since age dependency 
may be a disadvantage, natriuretic peptides without age dependency will favour the ones 
with age dependency. We found significant differences between natriuretic peptides in fa-
vour of ANP/NT-ANP over BNP/NT-proBNP and also of NT-proBNP over BNP, although 
differences appeared to be generally small. 
Relation ANP/NT-ANP, BNP/NT-proBNP and gender 
In healthy adults, gender differences in plasma levels of natriuretic peptides are found, 
with females having higher plasma levels.9,10,13 However, we only found a gender differ-
ence for ANP/NT-ANP and not for BNP/NT-proBNP. This might reflect the age difference 
between men and women; because BNP/NT-proBNP were shown to be more affected by 
ageing compared to ANP/NT-ANP, this age difference could be more powerful in BNP/NT-
proBNP.
Interpretation of the findings 
Age dependency of natriuretic peptides has been clearly shown in a healthy popula-
tion.8-10,19,20 We demonstrated that the influence of age on natriuretic peptides in CHF pa-
tients was modest, and comparable to several other factors, such as cardio-thoracic ratio, 
renal function and left ventricular ejection fraction. Therefore, indexing natriuretic peptides 
for age seems reasonable in case of diagnosis of CHF. However, when natriuretic peptides 
are used for prognosis or to guide medical treatment in patients already diagnosed with 
CHF, we do not recommend to routinely indexing natriuretic peptides for age. 
Limitations
First, the current study was relatively small. The majority of the patient population was 
male (76%), and in some age quartiles less than 20 females were present. Therefore, power 
was too small to draw definite conclusions regarding gender differences between ANP/NT-
ANP and BNP/NT-proBNP. 
Second, several other factors appeared to be related to the levels of some natriuretic pep-
tides, but not to others. This is in contrast to the age-dependency, which was demonstrated 
with all natriuretic peptides. Since we cannot clearly explain these findings, we think that 
these might have been due to chance finding. 
Third, measurements of plasma levels of NT-proBNP were performed using a non-com-
mercially available assay developed by Prof. O. Vuolteenaho (Oulu, Finland). The disadvan-
tage of using this assay is that no solid validation information is available. Because different 
assays have different outcomes, current results are only valid for the natriuretic peptide 
plasma levels determined with the same assays.Age, gender and natriuretic peptides
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Conclusions 
The present analysis confirmed the positive relation between ANP/NT- ANP, BNP/NT-
proBNP and age in a large group of CHF patients. In addition, the influence of age appeared 
to be more pronounced on levels of BNP/NT-proBNP than on ANP/NT-ANP. Also, the rela-
tive increase of BNP with age was significantly larger than of NT-proBNP. Nevertheless, 
many other factors were also related to plasma levels of both ANP/NT-ANP and BNP/NT-
proBNP, and partial correlation coefficients were relatively low.
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Abstract
Aims: Anaemia (by increasing plasma volume) and renal dysfunction (by decreasing clear-
ance) may affect B-type Natriuretic Peptide (BNP) and N-terminal proBNP (NT-proBNP) 
levels, although this has not been well described in heart failure (HF) patients. We therefore 
aimed to study the influence of anaemia and renal function on BNP and NT-proBNP levels 
in hospitalised HF patients. 
Methods and Results: We studied 541 patients hospitalised for HF, and BNP and NT-
proBNP levels were measured before discharge. Of these patients (71 ± 11 years of age, 62% 
males, left ventricular ejection fraction 0.33 ± 0.14), 30% (n=159) was anaemic (Hb<7.5 
mmol/L for women and Hb<8.1 mmol/L for men). Of the 159 anaemic patients, 73% had 
renal dysfunction (eGFR <60 ml/min/1.73m2) and of the non-anaemic patients, 57% had 
renal dysfunction. Multivariable analysis demonstrated that both plasma haemoglobin and 
eGFR were independently related to the level of both BNP and NT-proBNP (standardized 
beta’s of -0.20, -0.13 [BNP] and -0.26, -0.28 [NT-proBNP] respectively, P-values <0.01). 
Conclusion: Anaemia and renal dysfunction are related to increased BNP and NT-proBNP 
levels, independent of the severity of HF. Thus, false positive values of elevated BNP and NT-
proBNP levels can be anticipated in HF patients with anaemia and/or renal dysfunction. 
Introduction
The diagnostic accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP 
(NT-proBNP) in patients who are presented at the emergency department for acute dys-
pnoea is well described.1,2 However, even with optimal cut-off values determined by re-
ceiver operating characteristic curves, approximately 10% of the patients have false negative 
outcomes, and 16%-24% of the patients have false positive outcomes.1,2 To further increase 
the diagnostic accuracy of these natriuretic peptides, it is important to identify other fac-
tors, beside the severity of HF, that influence BNP levels and NT-proBNP levels. We and 
others have previously described that, in addition to its correlation with severity of HF,3 
both BNP and NT-proBNP levels are influenced by several other factors such as age, gender, 
obesity and renal function.4-11 
Another factor that might influence NT-proBNP levels and that is frequently found in 
patients with heart failure is anaemia. Since anaemia causes increased plasma volume in-
dependent of severity of HF,12 and because natriuretic peptides are released in reaction to 
ventricular plasma overload13 it is conceivable that natriuretic peptides are higher in anae-
mic HF patients compared to non-anaemic HF patients. In 209 patients without HF or renal 
disease Willis et al. recently demonstrated that NT-proBNP concentrations were significantly 
higher in patients with anaemia compared to patients without anaemia.14 In contrast, in a 
subgroup analysis of the Breathing Not Properly trial, no correlation was found between 
BNP levels and haemoglobin in 200 patients with systolic HF, and only a weak correlation 
was found between BNP levels and diastolic HF.15 In that study patients with renal failure 
were excluded. To our knowledge, the independent influence of anaemia on NT-proBNP 
levels has never been investigated in a HF population without exclusion of patients with 
renal failure. Moreover, we are not aware of any study investigating the influence of anaemia Anaemia, renal function, BNP and NT-proBNP
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and renal dysfunction on levels of BNP and NT-proBNP. Since renal dysfunction is a well 
known cause of anaemia16 and because it may influence both BNP levels and NT-proB-
NP levels by decreasing clearance,17 renal dysfunction should be taken into account when 
studying the effect of anaemia on BNP levels and NT-proBNP levels. Hence, the aim of the 
present study was to investigate the relationship between anaemia and renal function with 
BNP levels and NT-proBNP levels in HF patients. 
Methods
Study population
The present study complies with the Declaration of Helsinki, the local ethics committee 
has approved the research protocol and informed written consent has been obtained from 
the subjects. All patients in the present study were recently admitted for decompensated 
HF (NYHA II-IV), when they were included in a multicenter HF trial conducted in the 
Netherlands (COACH).18 All participating sites (n = 17) were experienced HF centre’s. 
Patients were at least 18 years of age with evidence of structural underlying heart disease. 
Detailed information on the study design has been published before.18 In short, COACH 
is a randomised controlled trial investigating the effect of education and counselling on 
readmission for HF and mortality. Of the 1049 patients included in the COACH study, 543 
patients had NT-proBNP levels available at baseline, 601 patients had BNP levels available at 
baseline, and 541 patients had both BNP and NT-proBNP levels available at baseline. Main 
reasons for missing BNP data were: no Triage® BNP meter available and the absence of a 
possibility to store plasma samples at - 80°C (n = 177), unplanned hospital discharge (n = 
75) or death during admission (n = 20). Main reasons for missing NT-proBNP data were: 
the start of the NT-proBNP sub study after already 272 patients were included in COACH, 
the absence of a possibility to store plasma samples at - 80°C (in 1 out of  17 clinics; n 
= 71), unplanned hospital discharge or logistical problems (n = 155) and death during 
admission (n = 9). 
Measurement of BNP and NT-proBNP levels
Blood was collected shortly before discharge between 8:00 AM and 4:00 PM, after pa-
tients had been clinically stabilised and were recovered well enough to go home. Ten millili-
tres of whole blood was taken from an antecubital vein and collected into tubes containing 
potassium ethylenediaminetetraacetic acid (EDTA; 1 mg/ml blood) when patients were in 
a supine position. The tubes were centrifuged for 10 minutes (2500 x g) and the plasma 
was separated and stored in polyepropene tubes at -70°C to -80°C. The plasma samples 
were transported (on dry ice) to the Core Laboratory at the University Medical Centre 
Groningen, the Netherlands.
BNP measurement: In 364 out of the 541 patients, BNP levels were determined on site in 
whole blood within 4 hours after blood collection. In 177 out of the 541 patients BNP levels 
were determined in plasma at the Core Laboratory. All measurements were performed using 
a fluorescence immunoassay kit (Triage®, Biosite Incorporated, San Diego, CA). Details on 
the system provided by the manufacturer indicated the analytical sensitivity of the assay is 
less than 5.0 pg/ml. The system has been validated before.19 The measurable range of the 
BNP assays was 5.0- 5000.0 pg/ml. Chapter 4
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NT-proBNP measurement: All measurements of NT-proBNP levels were performed in plasma 
at the Core laboratory on an Elecsys™ 2010 analyser, a commercially available electroche-
miluminescent sandwich immunoassay (Elecsys proBNP, Roche Diagnostics, Mannheim, 
Germany).  The intra-assay precision (coefficient of variation) is 1.2 – 1.5%, and the in-
ter-assay precision (coefficient of variation) is 4.4 – 5.0%, with an analytical range of 
5   – 35000 pg/ml.20,21
Anaemia
The definition of anaemia according to the World Health Organisation was used; Hb   
<7.5 mmol/l (12 g/dl) for women and Hb < 8.1 for men (13 g/dl). 22
Renal function
Serum creatinine was determined from a blood draw shortly before discharge, in the local 
laboratory at each centre. Estimated Glomerular Filtration Rates (eGFR’s) were calculated 
using the Levey – modified Modification of Diet in Renal Disease formula:23
eGFR (ml/min/1.73m2) = 186 x SCr-1.154 x age-0.203 x (0.742 if female) x (1.21 if black)
Boston score
For 501 out of the 541 patients with BNP and NT-proBNP levels available, the Boston 
score, a quantification related to severity of HF, was calculated.24 This score was used in 
combination with left ventricular ejection fraction (LVEF) to adjust possible determinants 
of BNP levels and NT-proBNP levels for severity of HF in the multivariable regression analy-
sis. In short, the score consists of a medical history sub score, a physical examination sub 
score and a chest radiography sub score. For each sub score, a maximum of 4 points is al-
lowed. The diagnosis HF is classified definite for a total score of 8 – 12 points, possible for a 
total score of 5 – 7 points and unlikely for a total score of 4 points or less. The Boston score 
was missing in 13 cases, since no chest radiography data were available of these patients. 
Statistical analyses
In order to study the independent relationship between anaemia haemoglobin (Hb) and 
renal function (as expressed in the eGFR) with BNP and NT-proBNP levels, univariable and 
multivariable linear regression analyses were performed in the patient population with 
both BNP and NT-proBNP levels available (n=541). Because the BNP and NT-proBNP levels 
had a skewed distribution the natural logarithm was used to get an optimal residual analy-
sis. To study potential confounding factors, the following variables were used in univariable 
analyses (Pearson and Spearman correlation coefficients when appropriate) with BNP and 
NT-proBNP as the dependent variables: age, gender, LVEF, the Boston score, New York Heart 
Association (NYHA) functional class, HF aetiology, duration of HF symptoms, pulmonal 
congestion, rales, heart rate, systolic and diastolic blood pressure, presence of atrial fibril-
lation/ flutter, presence of pacemaker, hematocrit, renal disease, body mass index (BMI), 
hypertension, pulmonary embolism, chronic obstructive pulmonary disease or asthma, 
diabetes mellitus (type 1 and 2), HF II medication at admission and at discharge (diuretics, 
ACE inhibitors/ angiotensin receptor blocker, beta-blockers, spironolactone). In the mul-
tivariable linear regression analysis, a stepwise approach was used. Besides Hb and eGFR, a 
univariable P-value < 0.15 was required to enter a variable into the multivariable model, 
and if the P-value was > 0.05 a variable was removed from the model. NT-proBNP or BNP Anaemia, renal function, BNP and NT-proBNP
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levels were presented in bar charts stratified by quintiles of Hb. To get more insight in the 
distribution of NT-proBNP and BNP across the ranges of Hb, ANOVA trend analyses were 
performed for NT-proBNP or BNP after these were divided by quintiles of Hb. The associa-
tions of the anaemia and renal function with NT-proBNP and BNP were presented in bar 
charts. Outcomes were considered significant when P<0.05. Values are presented as means 
± SD except when stated otherwise. All analyses were performed with SPSS version 11. 
Results
Study populations
Demographic and clinical characteristics of the 541 patients with both BNP and NT-proB-
NP available are presented in table 1. Mean age of these 541 patients was 71 (± 11) years, 
and more than half of the population was male (62%) and had a non-ischemic aetiology 
for HF (59%). On average, LVEF was 0.33 (±0.14), Hb was 8.4 (±1.2) mmol/l, eGFR 
was 54 (±20) ml/min/1.73m2 and BMI was 26 (±5) kg/m2. At discharge, patients were 
classified as NYHA functional class II (52%), III (46%) or IV (2%), and were on medical 
therapy including diuretics (88%), ACE inhibitors/ angiotensin II receptor blockers (71%), 
beta-blockers (61%) (table 1). Characteristics were not significant different between pa-
tients with available BNP/NT-proBNP levels (n=541) and the total patient group included 
in COACH (n=1049).
BNP and NT-proBNP levels
The median BNP value in the 541 patients with BNP and NT-proBNP available was 448 
pg/ml, the interquartile range 209 – 916 pg/ml, the minimum value 14 pg/ml and the 
maximum value 5000 pg/ml. The median NT-proBNP value was 2599 pg/ml, the inter-
quartile range 1314 – 5885 pg/ml, the minimum value 39 pg/ml and the maximum value 
75361 pg/ml (table 1). 
Anaemia
Hb levels were available in 528 of the 541 patients. BNP and NT-proBNP levels divided by 
quintiles of haemoglobin are presented in figure 1.  Anaemia was present in 30% (n=159) 
of the 541 patients in which BNP and NT-proBNP levels were available. Of these 159 anae-
mic patients 114 (73%) also had renal dysfunction (eGFR < 60 ml/min/1.73m2) and of 
the 369 non-anaemic patients 209 (57%) had renal dysfunction (figure 2).
Univariable determinants of BNP levels
Hb (P<0.001) and eGFR (P<0.01) were univariably related to the natural logarithm of 
BNP. Additionally, the following variables were potential confounders to these relation-
ships (P<0.15): age (P=0.11), LVEF (P<0.001), NYHA functional class (P=0.01), Boston 
score (P=0.14), ischemic/ non-ischemic aetiology of HF (P=0.04), pulmonary congestion 
(P=0.05), myocardial infarction before admission (P=0.12), systolic (P<0.01) and dia-
stolic blood pressure (P<0.01), atrial fibrillation/ flutter (P=0.11), hematocrit (P<0.001), 
BMI (P<0.001), prescribed diuretics at admission (P=0.06) . Chapter 4
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Table 1: Patient characteristics (n=541)
Demographics 
  Age (yrs)                             71 ± 11
  Gender (m) 62%
Heart failure/ physical examinations
  BNP (median [IQR], pg/ml) 448 (209 – 916)
NT-proBNP (median [IQR], pg/ml) 2599 (1314 – 5885)
  LVEF                                   0.33 ± 0.14
  NYHA at discharge (II, III, IV) 48%, 49%, 3%
  Ischemic/ non-ischemic HF 41% / 59%
  Duration HF symptoms (yrs)                               2.7 ± 4.5
  Pulmonal congestion (X-ray) 65%
  Rales during admission 89%
  Heart rate (bpm)                         74 ± 13
  Systolic BP (mm/Hg)              118 ± 21
  Diastolic BP (mm/Hg)                         69 ± 12
  Sinus rhythm 55%
  Atrial fibrillation/ flutter 38%
Medical History/ Co-morbidities
  Myocardial infarction 41%
  Hypertension 43%
  COPD/ Asthma 31%
  Diabetes (type1 or 2) 29%
  Renal diseases                         8%
  eGFR (ml/min/1.73m2)                                       54 ± 20
  Haemoglobin (mmol/l)                       8.4 ± 1.2
  Hematocrit (1/l)                                         0.41 ± 0.06
  Body Mass Index (kg/m2) 26 ± 5
Medication at admission
  Diuretics 65%
  ACE/ARB 45%
  Beta-blockers 40%
Medication at discharge
  Diuretics 88%
  ACE/ARB 71%
  Beta-blockers 61%
ACE/ARB = ACE inhibitor or Angiotensin Receptor Blocker, BNP= B-type Natriuretic Peptide, BP = Blood 
Pressure, COPD= Chronic Obstructive Pulmonary Disease, eGFR= estimated Glomerular Filtration Rate, 
HF= Heart Failure, LVEF= Left Ventricular Ejection Fraction, NT-proBNP = N-terminal pro B-type Natriuretic 
Peptide, NYHA= New York Heart Association functional class. Anaemia, renal function, BNP and NT-proBNP
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Figure 1: BNP (A) and NT-proBNP (B) (95% CI) divided by quintiles of Haemoglobin.Chapter 4
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Multivariable determinants of BNP levels
Hb and eGFR were independently related to the natural logarithm of BNP, and these 
relationships were confounded by BMI, LVEF and the Boston score (P-values ≤ 0.02). The 
interaction term of LVEF*eGFR added significant value to the multivariate regression model 
(standardised Beta = 0.11, P = 0.03). The R-square of the multivariable model was 0.21 
(table 2).
Univariable determinants of NT-proBNP levels
Hb (P<0.001) and eGFR (P<0.001) were univariably related to the natural logarithm of 
NT-proBNP. Additionally, the following variables were potential confounders to these rela-
tions (P<0.15): age (P<0.01), LVEF (P<0.001), NYHA functional class (P<0.01), Boston 
score (P=0.10), pulmonary congestion (P=0.01), systolic (P=0.03) and diastolic blood 
pressure (P=0.01), hematocrit (P<0.001), BMI (P<0.001), hypertension (P=0.14), pre-
scribed diuretics at admission (P<0.01) and prescribed diuretics at discharge (P=0.13).
Multivariable determinants of NT-proBNP levels
 Hb and eGFR were independently related to the natural logarithm of NT-proBNP levels, 
and these relations were confounded by BMI, LVEF and the Boston score (P-values ≤ 0.01). 
The interaction term of Boston score*LVEF added significant value to the multivariate re-
gression model (standardised Beta = 0.11, P = 0.02). The R-square of the multivariable 
model was 0.35 (table 2). 
Table 2: Multivariable linear regression analyses for the relationships of anaemia and renal function with 
lnNT-proBNP and lnBNP
lnNT-proBNP 
R2 = 0.35
lnBNP 
R2 = 0.21
Multivariable related St. Beta P-value St. Beta P-value
eGFR* -0.28 <0.001 -0.13                           0.001
Haemoglobin* -0.26 <0.001           -0.20 <0.001
* Corrected for body mass index, left ventricular ejection fraction and the Boston score. 
eGFR = Estimated Glomerular Filtration Rate, LnBNP = natural logarithm of B-type natriuretic Peptide plas-
ma levels, LnNT-proBNP = natural logarithm of N-terminal proB-type natriuretic Peptide plasma levels, St. = 
standardised. The interaction term between Boston score and LVEF added significant value to the multivari-
able model of lnNT-proBNP (Standardized Beta 0.11, P=0.02) and the interaction term between eGFR and 
LVEF added significant value to the multivariable model of lnBNP (Standardized Beta 0.11, P=0.03).Anaemia, renal function, BNP and NT-proBNP
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Figure 2: BNP levels (A) and NT-proBNP levels (B) (95% CI) divided by anaemia status and renal function
Anaemia was defined as Hb < 7.5 for women and Hb < 8.1 for men. Renal dysfunction was defined as eGFR 
< 60 ml/min/1.73m2.Chapter 4
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Discussion
The major finding of the present study is that both BNP levels and NT-proBNP levels 
are associated with anaemia and renal dysfunction, independent of the severity of heart 
failure. 
Anaemia and BNP/ NT-proBNP levels
Anaemia is a common phenomenon in HF, and is related to the severity of disease.25 
Although BNP and NT-proBNP are also related to severity of HF, the negative association 
between both BNP and NT-proBNP and Hb, as found in the present study, cannot only be 
explained by the severity of HF. Hb was related to BNP and NT-proBNP levels independent 
of severity of HF as measured by both LVEF and the Boston score. The present findings are 
in agreement with the results of Willis et al. on 209 patients without HF or renal failure.14 
They found that Hb added significant value to the multivariable linear regression model of 
NT-proBNP determinants. Another study in patients with suspected coronary artery disease 
(n=234) also showed an independent association between Hb and BNP levels.26 However, 
Wu et al. found no correlation between BNP levels and Hb in 200 patients with systolic HF, 
and only a small correlation was found between BNP and diastolic HF (n=121; r=0.047; 
p<0.05).15  The differences compared to our results might be explained by the exclusion of 
patients with renal dysfunction in this study by Wu et al.15  Since anaemia is often caused 
by renal insufficiency, a subgroup of HF patients without renal insufficiency does not fully 
represent HF patients in clinical practice and one might argue whether such a subgroup is 
the best to investigate the effect of anaemia on BNP levels. 
The most obvious explanation for the independent associations of anaemia with BNP/
NT-proBNP levels is that anaemia results in elevated plasma volume independent of severity 
of HF.12 Since BNP and NT-proBNP are released in reaction to ventricular plasma overload,13 
it is conceivable that BNP and NT-proBNP levels are higher in anaemic HF patients com-
pared to non-anaemic HF patients. Additionally, patients with anaemia and renal dysfunc-
tion showed higher BNP and NT-proBNP levels, compared to anaemic patients without 
renal dysfunction (figure 1, 2). This finding can be explained by previous findings, where 
renal dysfunction was found to be a major cause of anaemia in HF patients, mediated by a 
erythropoietin production deficiency in the kidneys.16 
Renal function and BNP/ NT-proBNP levels
Elevated levels of BNP were also independently related to renal dysfunction and, although 
not directly compared, this relation seemed less powerful than the relation between renal 
dysfunction and NT-proBNP (-0.13 vs. -0.28 respectively). This difference may be explained 
by differences in clearance. NT-proBNP is probably mainly cleared from the blood by the 
kidneys,17 while BNP is most likely mainly cleared by neutral endopeptidases and natriuretic 
peptide clearance receptors.27,28 This implies that the influence of renal dysfunction should 
be more pronounced on NT-proBNP levels compared to BNP levels. 
Implications for clinical practice
Our data indicate that haemoglobin and renal function should be taken into account 
when interpreting elevated levels of BNP and NT-proBNP. Although elevated levels naturally Anaemia, renal function, BNP and NT-proBNP
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could be related to worsening of heart failure, they can also be caused by anaemia or renal 
dysfunction, while the severity of heart failure remains unchanged.
Conclusions
In this large group of hospitalised heart failure patients, lower haemoglobin levels and 
worse renal function were independently associated with elevated BNP levels and elevated 
NT-proBNP levels. These results indicate that in HF diagnosis BNP levels but especially NT-
proBNP levels might be overestimated in patients with renal dysfunction and/or anaemia. 
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Abstract
Background: B-type Natriuretic Peptide (BNP) and 6-minute walk test (6MWT) are both 
related to severity and prognosis in chronic heart failure (CHF), but may reflect different 
aspects of CHF. We related BNP and 6MWT to left ventricular ejection fraction (LVEF), New 
York Heart Association functional class (NYHA), and 2 indices of quality of life (physical 
subscales): the Minnesota Living with Heart Failure Questionnaire (MLwHFQph) and the 
RAND-36ph. 
Methods: Plasma BNP and 6MWT were measured at discharge in 229 patients who had 
been admitted for CHF. LVEF and NYHA were determined, and patients completed the 
MLwHFQ and RAND-36 questionnaire. 
Results: BNP was weakly correlated to LVEF (r=-0.29, P<0.01), and NYHA (r=0.20, 
P<0.01), but not to MLwHFQph and RAND-36ph. On the other hand, 6MWT is related to 
the MLwHFQph (r=-0.23, P<0.01), the RAND-36ph (r=0.52, P<0.01) and to the NYHA 
(r=-0.46, P<0.01), but not to LVEF (r=-0.15, P=0.05). There is also no correlation be-
tween BNP and 6MWT (r=-0.01, P=0.87). 
Conclusions: The present data show, that BNP and 6MWT represent different aspects of the 
clinical syndrome of CHF. The outcomes of this study suggest that BNP plasma levels are 
more related to cardiac function, while 6MWT reflects functional capacity and quality of 
life. 
Introduction
B-type Natriuretic Peptide (BNP) plasma levels and 6 minute walk test (6MWT) are 
related to severity1-3 and prognosis4,5 in chronic heart failure (CHF). BNP plasma levels reflect 
stretch and tension of the myocardial wall6,7 and 6MWT is used to measure submaximal 
functional capacity of CHF patients.3
Older studies have suggested a very weak relationship between (peak) exercise functional 
capacity and parameters of cardiac function, such as left ventricular ejection fraction (LVEF) 
in CHF patients.8-11 Dracup et al. also found no correlation between LVEF and 6MWT, which 
is generally considered a measure of submaximal exercise capacity.10 Other investigators 
showed that exercise intolerance in CHF patients was more related to peripheral abnor-
malities than to central cardiac function.12,13 Despite this, two recent relatively small stud-
ies, performed in an outpatient clinic setting, showed a significant and positive correlation 
between BNP and 6MWT in patients with CHF.14,15 
Quality of life is one of the hallmarks of the CHF syndrome, and is increasingly being 
recognized as an important target for treatment.16  The 6MWT is related to the physical 
dimensions of quality of life measured using the Heart Failure Functional Status Inventory 
questionnaire10  and to daily activities.17,18 BNP has become an important tool in the clinical 
assessment of CHF patients, but its relation with indices of quality of life is less well 
examined. 
Accordingly, we determined BNP and 6MWT at discharge after a hospital admission 
for CHF, and related these parameters to cardiac function (LVEF) and symptoms (NYHA 
functional class), as well as to 2 indices of quality of life (physical subscales): the Minnesota 
Living with Heart Failure Questionnaire (MLwHFQph) and the RAND-36ph. BNP, functional status and quality of life
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Materials and methods
Study population 
All patients in the present study were part of a multicenter CHF trial conducted in the 
Netherlands. The design, inclusion and exclusion criteria have been described elsewhere.9 
All patients were admitted for symptomatic CHF (NYHA II- IV), and none of them had a 
cardiogenic shock. Patients were at least 18 years of age with evidence of structural under-
lying heart disease. Two hundred and twenty nine CHF patients, with complete datasets of 
BNP and 6MWT, were included in the analysis. The study was approved by a central Ethical 
Committee, and all patients provided informed written consent. The study protocol con-
forms with the ethical guidelines of the 1975 Declaration of Helsinki.
BNP measurement 
At the day of hospital discharge or the day before hospital discharge, between 8:00 AM 
and 16:00 PM, 5 ml of whole blood was taken from an antecubital vein and collected 
into tubes containing potassium ethylenediaminetetraacetic acid (EDTA) (1 mg/ml blood). 
Within 4 hours after blood collection BNP plasma levels were determined using a fluores-
cence immunoassay kit (Triage®, Biosite diagnostics Inc. San Diego CA). Precision, analytic 
sensitivity and stability characteristics of the system have previously been described.21 The 
measurable range of the BNP assays was 5.0- 5000.0 pg/ml. 
Functional capacity
At the day of blood collection, patients performed a 6MWT on a predefined course in 
a hospital corridor. Patients were instructed to walk as many meters as they could within 
6 minutes. At standardized moments the instructor told the patients the amount of time 
remaining and patients were allowed to stop or slow down if necessary. The 6MWT is a 
reliable and well validated test in CHF patients.22
Physical dimension of quality of life 
Physical functioning was measured by two different questionnaires. Perceived physical 
functioning was measured by one out of eight dimensions of the RAND-36 Health Survey: 
RAND-36 physical functioning (RAND-36ph). The range of the RAND-36ph was 0-100 
with higher scores mean better perceived physical functioning. Physical functioning related 
to CHF was measured by the Minnesota Living with Heart Failure questionnaire subscale 
of physical functioning (MLwHFQph). The range of the MLwHFQph was 0 to 40 with 
higher scores mean worse quality of life. These two questionnaires are reliable and well 
validated.23,24  Patients completed the questionnaires during their hospital admission.
Additional demographic and clinical data were collected by chart review. 
Statistical analysis 
Because the plasma BNP had a skewed distribution the natural logarithm was used to get 
an optimal residual analysis. Pearson or Spearman correlation coefficients were calculated 
between lnBNP, 6MWT, New York Heart Association functional class (NYHA), LVEF, ML-
wHFQph and RAND36ph, when appropriate. Outcomes were considered significant when 
P<0.05. Values are presented as means ± SD except when stated otherwise.Chapter 5
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Table 1: Characteristics of study population (n=229).
Demographics
Age (years)                         70 ± 12
Gender (men) 63%
Clinical parameters
NYHA II, III, IV 58, 40, 2%
LVEF                                                                           35 ± 14%
HR (beats . min-1)                       74 ± 13
Blood pressure (mmHg)
Systolic             119 ± 21         
Diastolic                 69 ± 11
Body mass index (kg/m2)                        27 ± 15
Pulmonary congestion  73%
Heart failure cause
Ischemic 41%
Non-ischemic 59%
Medical history
Previous myocardial infarction 41%
Atrial fibrillation 39%
Hypertension 33%
COPD 23%
Type II diabetes mellitus 23%
Peripheral vascular disease  16%
Renal disease 5%
Duration hospitalization (days)                   12 ± 9
Medical treatment at discharge
Diuretics  94%
ACE inhibitors and/or ARB 84%
Beta blockers 59%
Spironolacton 32%
Study variables
Median, 25th and 75th percentile of BNP (pg/ml) 530, 245, 1050
6MWT distance (meter)                       259 ± 119
MLwHFQph (range: 0-40)                                 23 ± 10
RAND36ph (range: 0-100)                                 36 ± 27
NYHA= New York Heart Association functional class, LVEF= Left Ventricular Ejection Fraction, HR= Heart 
rate, COPD= Chronic Obstructive Pulmonary Disease, ARB= A-II receptor antagonist, BNP= B-type natri-
uretic peptide, 6MWT= 6 Minute Walk Test, MLwHFQph= physical subscale of Minnesota Living with Heart 
Failure Questionnaire, RAND36ph = RAND 36-item Health Survey physical functioning subscale.BNP, functional status and quality of life
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Results
Study population
Demographic and clinical characteristics of the 229 patients are presented in table 1. On 
average patients were 70 ± 12 years of age and the majority (63%) of patients was male. 
More than half of the patients had a non-ischemic primary reason for CHF, and most of 
them were in NYHA functional class II or III (58%, 40% respectively), and were on medical 
therapy including diuretics, ACE inhibitors and Beta blockers (table 1). 
Study variables 
The median and 25th, 75th percentile of BNP in the sample was 530, 245, 1050 pg/
ml. On average patients walked 259 ± 119 meters in 6 minutes. The average score on the 
MLwHFQph was 23 ± 10 and on the RAND36ph 36 ± 27 (table 1). 
Correlations
lnBNP showed a weak correlation to LVEF (r= -0.29, P<0.01) and NYHA (r=0.20, P<.01), 
but not to the indices of quality of life (table 2). In contrast, 6MWT was significantly related 
to both MLwHFQph (r= -0.23, P<0.01) and the RAND36ph (r=0.52, P<0.01) and also 
to NYHA class (r= -0.46, P<0.01); there was no significant correlation to LVEF (table 2). 
Additionally, lnBNP was not associated to 6MWT (r= -0.01, P=0.87) (figure 1).
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Figure 1: Correlation between InBNP and BMWT distance (n=229)Chapter 5
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Discussion
The main finding of the present study is that BNP plasma levels are related to LVEF, but 
not to parameters which reflect quality of life, in particular those that are related to physical 
discomfort. In contrast to BNP, the 6MWT shows a significant relation to these parameters 
(MLwHFQph and RAND36ph), but not to LVEF. Furthermore, in agreement with other 
studies,1-3  we found a correlation between BNP and symptoms of CHF (NYHA functional 
class) and also between 6MWT and NYHA functional class. Although correlation coef-
ficients are relatively weak, the present results show that reduced cardiac function is not 
necessarily associated with decreased submaximal functional capacity in CHF. 
BNP secretion rises in the case of decreased left ventricular function, due to stretch and 
tension of the ventricular wall.25 Indeed, BNP may thus be a good reflection of cardiac 
function. However, BNP plasma levels can vary in a short period of time due to biological 
variation,26  physical activity27 and change in medication.28,29 Accordingly, Kazanegra et al. 
showed that BNP plasma levels decreased significantly within 24 hours, simultaneous to 
peak capillary wedge pressure, after treatment was given with diuretics, vasodilators and 
inotropic drug agents.30
On the other hand, the 6MWT is a measure of physical dimensions of quality of life and 
submaximal functional capacity. It probably reflects more gradual changes and thus may be 
a more global reflection of severity of disease.22,31 During the progression of CHF, skeletal 
muscle properties change; strength reduces and fatigue appears sooner. As a result patients 
have limited functional capacity.11 
In 78 stable CHF patients, Tjeerdsma et al. showed a significant correlation between BNP 
and maximal exercise tolerance (peak VO2; r = -0.52, P < 0.001).21 It cannot be excluded 
that a correlation between BNP and peak VO2 might have existed in our study population 
as well. However, no sufficient data on peak VO2 were available (n=12).
In contrast, in the present study population there was no correlation between BNP and 
6MWT at hospital discharge after admission for CHF. This finding is in contrast to two other 
outpatient studies.13,14  The patients in these two studies, however, were in different stages 
of their disease, and not all of them were clinically stable. Our present population consisted 
Table 2: Correlation matrix (n=229).
lnBNP
r
P-value 6MWT
r
P-value
LVEF -0.29 <0.01 -0.15                                 0.05
NYHA                   0.20 <0.01             -0.46 <0.01
MLwHFQph                 0.03                                 0.67       -0.23 <0.01
RAND36ph                                   -0.002                                   0.97                   0.52 <0.01
lnBNP = lnB-type Natriuretic Peptide, 6MWT = 6 Minute Walk Test, LVEF = Left Ventricular Ejection Fraction, 
NYHA = New York Heart Association functional class, MLHFQph = Minnesota Living with Heart Failure 
Questionnaire physical subscale, RAND36ph = RAND 36-item Health Survey physical functioning subscale.BNP, functional status and quality of life
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of patients who had been recently hospitalized for symptomatic CHF which most probably 
influenced the measurements of BNP and 6MWT. At the time of discharge, however, these 
patients were clinically stable. It is conceivable that by that time, BNP levels had significantly 
dropped or even normalized, as compared to possibly high levels at admission to the hospi-
tal.28,29  The improvement in 6MWT probably takes much longer than the normalization of 
BNP plasma levels, which might explain the dissociation between these parameters in the 
setting of discharge after admission for CHF.
Limitations
In the current study population many patients (23%) had COPD as co-morbidity, which 
might have influenced the study results. However, when patients with COPD were excluded 
from the analysis, the correlation coefficient between lnBNP and 6MWT only changed 
slightly (r = -0.11, P-value = 0.15). Furthermore, in clinical practice a significant propor-
tion of CHF patients also has COPD. Hence, our study population reflects the CHF popula-
tion of the clinical practice.
Conclusion 
These results suggest that BNP is more related to cardiac function, while 6MWT reflects 
functional capacity and quality of life. Therefore, BNP plasma levels and functional capacity 
as measured by the 6MWT reflect different aspects of CHF although both are important 
parameters, and have been shown to be related to clinical outcome.
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Editor,
In the current era of growing incidence and prevalence of chronic heart failure (CHF), 
the functional status assessment of CHF patients is increasingly needed, as it is one of the 
tools to investigate severity of CHF. B-type natriuretic peptide (BNP) is gradually more used 
in the diagnosis, prognosis and management of CHF patients. Since BNP is an easy, cheap 
and readily available test, an investigation that evaluates the value of BNP in functional status 
assessment is important. 
In their recent paper in Cardiovascular Drugs and Therapy Abdulla et al. evaluate the potential of 
BNP as a surrogate marker for traditional methods of assessing functional status of patients 
with left ventricular systolic dysfunction.1 The authors describe a meta-analysis of four 
articles that all reported the correlation between BNP and functional status as assessed by 
either peak VO2 or 6-minute walk test. Because the meta analysis showed only a moderate 
correlation (r=-0,59), the authors carefully concluded that the traditional methods should 
still be considered as standard methods in assessing functional capacity. We agree with this 
conclusion, but we would like to add some strength to it and support the notion that BNP 
is not a good marker for measuring functional capacity. Also we would like to make few 
comments.
First, we noticed that two relevant papers were not included in the meta analysis. These 
studies by Brunner-La Rocca et al.2 and Kinugawa et al.3 also described the correlation 
between BNP and peak VO2 in a tertiary care centre and an outpatient clinic setting respec-
tively. Both studies reported a very low correlation coefficient between BNP and peak VO2 
(r≤-0.33), and adding these studies would have further weakened the moderate correlation 
as found in the meta analysis by Abdulla et al.
Second, the authors do not mention the clinical setting of the studies they reviewed. The 
studies were all performed in an outpatient clinic setting, making the results difficult to 
generalize to the total CHF population.
We recently studied a group of 120 CHF patients at time of discharge after admission 
for CHF (age 70 ± 12 years, 58% males, left ventricular ejection fraction 34 ± 14%, 41% 
ischemic aetiology of CHF). BNP was assessed and 6-minute walk test was performed on the 
day before discharge from the hospital. No correlation between BNP and functional status 
(6 minute walk test) was found (r=0.005, P=0.95).4 Therefore we argue that the clinical 
setting should be taken into account when conclusions are drawn about the correlation 
between BNP and functional status. 
As stated by the authors, BNP is a very valuable marker in the management of CHF, but 
its plasma levels can change due to several variables like age, gender, renal function, use of 
medication, body weight. We want to stress the importance of the clinical setting, especially 
when evaluating the relationship between BNP and functional status.BNP, functional status and quality of life
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BNP and functional status in heart failure (response)
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mark.
We would thank Hogenhuis et al. for their worthy commentary letter on our article.1 We 
agree with the authors that the two studies they mentioned2,3 should also be included in the 
meta-analysis. Therefore we have reanalysed the data including these two studies, the result 
showed a weaker correlation (Table 1). When we also combined the result of the recently 
published study by the authors (Hogenhuis et al.) on 120 patients before hospital dis-
charge4 the correlation was even weaker R = −0.41. Our aim was to demonstrate in general 
that brain natriuretic peptide (BNP) levels are poorly correlated to the functional status and 
BNP measurement seems not to be a reliable surrogate in this setting; however, we agree 
with the authors that the clinical setting of patients with heart failure is also important.
Table 1. The studies that evaluated the correlation between resting brain natriuretic peptide (BNP) levels and 
functional status in patients with left ventricular systolic dysfunction (LVSD) in outpatient clinic.
No.
Author of the study and 
publication year
Population and 
aetiology 
of LVSD
Methods used to assess functional status and 
its correlation to plasma BNP level expressed 
as R and p-values
1 Brunner-La Rocca 1999 2 N=48 IHD 58%, 
Non-IHD 42%
Symptoms R= −0.48, p = 0.001 
Treadmill test measuring PVO2 R= −0.31, p < 
0.05
2 Krüger 2002 5 N = 70 IHD 40%, 
Non-IHD 60%
Bicycle ergometer measuring PVO2 R= −0.56, 
p < 0.001
3 Tjeerdsma 2002 6 N = 78 Aetiology 
unavailable
NYHA R= 0.83, p < 0.0001 Treadmill test meas-
uring PVO2 R= −0.52, p < 0.001
4 Jourdain 2002 7 N = 151 IHD 63%, 
Non-IHD 37%
NYHA p < 0.0016-MWT (distance) R= −0.69, 
p < 0.001
5 Kinugawa 2003 3 N = 84 IHD=17%, 
Non-IHD 83%
Bicycle ergometer measuring PVO2 R= −0.33, 
p=NS
6 Wieczorek 2003 8 N = 44 IHD = 57%, 
Non-IHD 43% 6-MWT (distance) R= −0.47, p = 0.001
Combined meta-analytic result
N = 475 IHD = 47%, 
Non-IHD = 53%
Correlation of all exercise variables to 
BNP (PVO2 and 6-MWT) R= −0.52
N = number, NYHA = New York Heart Association, IHD = Ischaemic heart disease, PVO2 = Peak oxygen 
uptake, 6-MWT = 6 minutes walk test, NS = not significant, R = correlation coefficient.BNP, functional status and quality of life
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Abstract
Background: Previous studies showed that 18% -33% of patients admitted for suspected 
heart failure (HF) receive a false-positive discharge diagnosis of heart failure. We aimed to 
identify the most important independent predictors of a (false) HF discharge diagnosis to 
construct a score to improve the discharge diagnosis of HF.
Methods: Using univariable and multivariable logistic regression and Receiver Operating 
Characteristics (ROC) analysis, the value of potentially important diagnostic determinants 
including B-type Natriuretic Peptide (BNP) and N-terminal proBNP (NT-proBNP) was as-
sessed and combined in a scoring rule.
Results: In the present study population (n = 540, 71 ± 11 years of age, 62% male), an 
outcome panel identified 6% with a discharge diagnosis other than HF. Univariable pre-
dictors of the discharge diagnosis HF were dyspnoea at rest, absence of COPD/ asthma, 
absence of anaemia, renal dysfunction, BNP > 100 pg/ml and NT-proBNP > 300 pg/ml. 
In multivariable logistic analyses, all of these, except BNP > 100 pg/ml, remained inde-
pendent predictors of a HF discharge diagnosis. The ROC area of a model combining these 
predictors was 0.78. 
Conclusion: In our population, a discharge diagnosis other than HF occurred in only 6% 
of the patients. Four readily available patient characteristics together with NT-proBNP are 
independent predictors of a discharge diagnosis of patients admitted for suspected HF, and 
these were combined in a scoring rule to optimize the discharge diagnosis of these patients. 
This score should be validated in other populations before its use in clinical practice can 
be recommended. 
Introduction
Discharge diagnoses have been instrumental in providing estimates of and time trends in 
the incidence of heart failure (HF). However, studies in the Netherlands, the United States 
and in Sweden showed that respectively 20%, 33% and 18% of the patients hospitalized for 
HF receive a false-positive discharge diagnosis of HF,1-3 which may suggest that up to one 
third of the patients in these studies may be discharged without optimal medical treatment, 
which may lead to inappropriate care and unnecessary high expenses. 
Although B-type Natriuretic Peptide (BNP)4 and N-terminal pro BNP (NT-proBNP)5 are 
known to be useful in the emergency diagnosis of HF, little evidence is available on their 
diagnostic value in establishing the discharge diagnosis in patients admitted for suspected 
HF. When BNP or NT-proBNP is an independent predictor of a HF discharge diagnosis 
in these patients, it could be combined with routinely available patient characteristics to 
develop a scoring rule to be applied in clinical practice. Therefore, we aimed to: 1) investi-
gate whether NT-proBNP, BNP and routinely available patient characteristics, including co- 
morbidity, are independent predictors of the discharge diagnosis of HF in patient admitted 
with suspected HF and 2) develop a score combining the most important predictors of a 
HF discharge diagnosis.  Discharge diagnosis with NT-proBNP
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Methods 
Study population 
All 540 patients in this study were recently admitted for suspected HF (NYHA II-IV), 
and were included in a multicenter HF trial conducted in the Netherlands (COACH). 6 Data 
for the present study were collected before randomization. All participating sites (n = 17) 
were centres with vast experience in HF care. Patients were at least 18 years of age and 
admitted with a clear suspicion of heart failure. The design, inclusion and exclusion criteria 
of the trial have been described in detail elsewhere.6 In short, COACH is a randomized 
controlled trial investigating the effect of education and counselling on readmission for HF 
and mortality. 
Availability and measurement of BNP and NT-proBNP levels 
Of the 1049 patients included in the COACH, 541 patients had both BNP and NT-proBNP 
plasma levels available. Temporary, usually in the starting phase of the study, unavailability 
of the necessary laboratory facilities was the main reason for missing BNP and NT-proBNP 
data. Blood was collected shortly before discharge between 8:00 AM and 4:00 PM, after 
patients had been clinically stabilised and recovered enough to go home. Ten millilitres 
of whole blood was taken from an antecubital vein and collected into tubes containing 
potassium ethylenediaminetetraacetic acid (EDTA; 1 mg/ml blood) when patients were in 
a supine position. The tubes were centrifuged for 10 minutes (2500 x g) and the plasma 
was separated and stored in polyepropene tubes at -70°C to -80°C. 
BNP measurement: In 364 out of the 541 patients, BNP levels were determined on site in 
whole blood within 4 hours after blood collection. In 177 out of the 541 patients BNP 
levels were determined in plasma at the Core Laboratory at the University Medical Center 
Groningen. All measurements were performed using a fluorescence immunoassay kit (Tri-
age®, Biosite Incorporated, San Diego, CA). Details on the system provided by the manu-
facturer indicated the analytical sensitivity of the assay is less than 5.0 pg/ml. The system 
has been extensively validated.7 The measurable range of the BNP assays was 5.0- 5000.0 
pg/ml.  
NT-proBNP measurement: All measurements of NT-proBNP levels were performed in plasma 
at the Core laboratory on an Elecsys™ 2010 analyser, a commercially available electroche-
miluminescent sandwich immunoassay (Elecsys proBNP, Roche Diagnostics, Mannheim, 
Germany). The intra-assay precision (coefficient of variation) is 1.2 – 1.5%, and the in-
ter-assay precision (coefficient of variation) is 4.4 – 5.0%, with an analytical range of 5 
– 35000 pg/ml.8,9 
Renal function 
Serum creatinine was determined from the blood drawn shortly before discharge, in 
the local laboratory at each centre. Estimated Glomerular Filtration Rates (eGFR’s) were 
calculated using the Levey – modified Modification of Diet in Renal Disease formula:10
eGFR (ml/min/1.73m2) = 186 x SCr-1.154 x age-0.203 x (0.742 if female) x (1.21 if black) 
Renal dysfunction was defined as an eGFR < 60 ml/min/1.73m2.Chapter 6
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Anaemia
The definition of anaemia according to the World Health Organisation was used; haemo-
globin levels < 7.5 mmol/l (12 g/dl) for women and < 8.1 for men (13 g/dl).11
Determination of discharge diagnosis i.e. reference (or ‘gold’) standard 
Two cardiologists that were blinded to BNP and NT-proBNP plasma levels reviewed the 
discharge reports of the 540 patients that were admitted for suspected HF. These reports 
included information on physical examination, medical history and the results of ECG, ra-
diological examinations, laboratory blood tests, echocardiography and effects of treatment. 
To determine the actual discharge diagnoses of these patients, the cardiologists indepen-
dently classified the discharge diagnosis as ‘HF’ or ‘other discharge diagnosis’. In case of 
disagreement about the discharge diagnosis between the two cardiologists, they discussed 
the discharge diagnosis until agreement was reached. The cardiologists could not draw any 
conclusion about the discharge diagnosis of one patient because the discharge report did 
not contain sufficient information. This patient was excluded from the analysis.
Statistical analyses 
To prevent chance findings we a priori decided to study a limited number of potential 
diagnostic determinants. Selection of the 11 variables was based on the literature and avail-
ability in every day practice. Univariable logistic analyses were performed to identify which 
variables were associated with the discharge diagnosis HF. Because BNP and NT-proBNP 
levels had a skewed distribution, the levels were dichotomized (BNP below or above or 
equal to 100 pg/ml4 and NT-proBNP below or above or equal to 300 pg/ml5 was used. A p-
value <0.15 was required to enter a variable into the multivariable logistic analyses. Either 
BNP or NT-proBNP was included in the multivariable regression analysis (and not both of 
these) because of the danger of multicollinearity and, first and foremost, because in clinical 
practice usually only one of the two is available. A Lemeshow and Hosmer goodness of fit 
statistic was calculated to evaluate the fit of the multivariable logistic regression model. The 
diagnostic performance of the combination of independent predictors (p-value < 0.05 in 
the multivariable analysis) was quantified by calculating the area under the receiver operat-
ing characteristic (ROC) curve. An ROC area of 0.5 signifies no discriminatory value (like a 
flip of a coin), while an area of 1.0 means perfect discrimination between those with and 
without a HF discharge diagnosis.
Since any model is too optimistic when the model is used on the dataset from which it 
was developed (over fitting), we used bootstrapping techniques in order to internally vali-
date the final multivariate model and to adjust the estimated ROC area under the curve and 
regression coefficients. The performance of a model after bootstrapping is more in concor-
dance with the performance that can be expected in future patients.12,13
Eighteen patients had 27 missing values. Since missing values usually do not occur at 
random, deletion of subjects with a missing value may lead to biased results and loss of 
power. Hence, we imputed any missing values by using a regression method with the ad-
dition of a random error term (SPSS version 11.0). The imputation was based on the cor-
relations between each variable with missing values and all other variables from the 522 
(97%) complete datasets.
In order to create an easy applicable diagnostic rule or score, we transformed the original Discharge diagnosis with NT-proBNP
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regression coefficients (after adjustment for over fitting) of the variables in the final model 
to points according to their relative contribution to the estimation of the discharge diagno-
sis. We calculated the score for each patient and estimated the absolute percentages of cor-
rectly diagnosed patients across score categories. To allow the construction of a diagnostic 
points score haemoglobin and eGFR were dichotomised into presence of anaemia (accord-
ing to WHO definition) and renal dysfunction (< 60 ml/min/1.73m2) respectively.
The analyses were performed with S-Plus version 6.1 except for the imputation procedure, 
as stated above.
Results 
Demographic and clinical characteristics of the 540 patients are presented in table 1. 
Mean age of the 540 patients was 71 (± 11) years, and more than half of the population 
was male (62%). The characteristics were not significantly different between patients with 
available BNP/NT-proBNP levels (n=540) and the total patient group included in COACH 
(n=1049).
The consensus panel classified 506 patients (94%) with a discharge diagnosis of heart 
failure, and in 34 patients (6%) another discharge diagnosis was established. These included: 
acute myocardial infarction, unstable angina pectoris, atrial fibrillation, chronic obstructive 
pulmonary disease (COPD)/asthma and pulmonary embolism. 
Table 1: Association between patients characteristics and the discharge diagnosis in patients admitted with 
suspected heart failure. Results from the univariable analysis. 
Heart Failure as 
discharge 
diagnosis (n=506)
Other discharge 
diagnosis 
(n=34)
Odds ratio 
(95% CI)
P-value
Age (y) 71 ± 11 69 ± 11   1.01 (0.98 – 1.04) 0.45
Gender (m) 62% 62% 0.98 (0.48 – 2.00) 0.95
NYHA   (II-III / IV) 60% / 40% 83% / 17% 3.15  (1.28 – 7.75) 0.01
Cardiovascular history* 73% 68%         1.15 (0.56 – 2.35) 0.70
Previous HF 
hospitalizations > 1
35% 32%                     1.11 (0.53 – 2.34) 0.77
AF/flutter 39% 29%               1.52 (0.71 – 3.24) 0.28
Hb (mmol/l)   8.5 ± 1.2 8.0 ± 1.5         1.32 (1.00 – 1.76) 0.05
eGFR (ml/min/1.73m2)                 53 ± 20     60 ± 22 0.98 (0.97 – 1.00) 0.05
COPD/ asthma 29% 50% 0.41 (0.20 – 0.82) 0.01
BNP > 100 pg/ml 91% 79%                                       2.7 (1.12 – 6.58) 0.03
NT-proBNP > 300 pg/ml 97% 82%                           6.56 (2.38        –        18.06) <0.01
AF= atrial fibrillation, BNP= B-type natriuretic peptide, COPD= chronic obstructive pulmonary disease, 
eGFR= estimated Glomerular Filtration Rate, Hb= haemoglobin, HF= heart failure, NYHA= New York 
Heart Association functional class at admission. * = previous MI, CVA, TIA, CABG or PTCA, DM 1 or 2 
and BMI > 30.Chapter 6
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The median BNP value of the patients with HF as discharge diagnosis was 459 pg/ml (in-
terquartile range 212 – 938 pg/ml), and the median BNP value of the patients with another 
discharge diagnosis was 297 pg/ml (interquartile range 135 – 632 pg/ml). The propor-
tion of patients with BNP > 100 pg/ml differed between the two groups (91% vs. 79%; 
P=0.03). The median NT-proBNP value of the patients with a HF discharge diagnosis was 
2718 pg/ml (interquartile range 1379 – 6168 pg/ml), while the value in patients with 
another discharge diagnosis was 1501 pg/ml (interquartile range 739 – 4920 pg/ml). 
The proportion of patients with NT-proBNP > 300 pg/ml was 97% and 82%, respectively 
(p<0.01) (table 1).
The following variables were associated with the discharge diagnosis ‘HF’ (p<0.15) in 
the univariable analysis: BNP > 100 pg/ml, NT-proBNP > 300 pg/ml, dyspnoea at rest 
(NYHA class IV) at hospital admission, absence of COPD / asthma, higher haemoglobin 
and lower eGFR (table 1). After bootstrapping, exactly the same variables showed p-values 
< 0.15, although the individual odds ratios slightly changed. 
All of these, except BNP, were independent predictors of the discharge diagnosis HF 
the multivariable analyses, and the Lemeshow and Hosmer goodness of fit statistic of the 
model was 5.0 (p=0.76). The ROC area of the combination of these 5 items was 0.78 (95% 
confidence interval 0.70-0.86; figure 1). Internal validation of the multivariable model by 
means of bootstrapping techniques yielded an ROC area of 0.67. Regression coefficients 
were rounded tot whole points according to their relative contribution to the discharge 
diagnosis (table 2). The score ranged from 0 to 14 point. For each score category, sensitivity, 
specificity and predictive values were calculated (table 3). 
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Figure 1: Receiver Operating Characteristics curve for discharge diagnosis HF. 
Area under curve: 0.78 (0.70 – 0.86)Discharge diagnosis with NT-proBNP
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Discussion
Dyspnoea at rest (NYA class IV), absence of COPD/Asthma, renal dysfunction, absence of 
anaemia and NT-proBNP > 300 pg/ml are independent predictors of a discharge diagnosis 
of HF in patients admitted to hospital with suspected HF. 
In contrast to previous studies, where 18%, 20% and 33% of HF discharge diagnoses 
were false-positive,1,3 we found that only 6% of the patients that were admitted with sus-
pected HF did not have HF as the discharge diagnosis after close examination of all available 
information. This is at least partly attributable to the patient selection typically involved in 
randomized trials and more the rigorous evaluation (more intensive monitoring) of pa-
tients in such studies. In addition, it also reflects the experience of the participating clinics 
and cardiologists. Because of the low number of non HF discharge diagnoses we limited the 
number of diagnostic determinants to be evaluated. 
Table 2: Independent predictors (and their points assigned in the score) of a discharge diagnosis of heart 
failure in patients admitted with suspected heart failure. Results from multivariable logistic regression analy-
ses. 
Variables OR (95% CI) P-value Points for rule
Absence of anaemia     2.10 (0.97 – 4.54) 0.02 2
NYHA class IV             2.51 (0.98 – 6.43) 0.01 3
Absence of COPD/ Asthma 2.01 (0.96 – 4.19) 0.01 2
Renal dysfunction 
(eGFR<60ml/min/1.73m2)
        2.07 (0.97 – 4.40) <0.01 2
NT-proBNP>300pg/ml     4.95 (1.62 –15.15) <0.001 5
Table 3: Sensitivity, specificity and predictive values of different categories of the score.  
Risk category of 
simplified model 
(points)
Heart failure 
as discharge 
diagnosis
(n=506)
Other discharge 
diagnosis
(n=34)
Sensitivity
 
Specificity PPV NPV
Very low (0)
n=0
- - - - - -
Low (2-5) 
n=24
                          16 (67%) 8 (33%) 96% 6% 94% 9%
Medium (6-9) 
n=222
203 (91%) 19 (9%) 93% 26% 95% 21%
High (10-14)
n=276
270 (98%) 6 (2%) 53% 18% 91% 2%Chapter 6
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Our study identified other determinants of a diagnosis of HF than studies in other set-
tings. Previous studies in an emergency department setting showed that age, history of HF, 
previous myocardial infarction, hypertension, rales, pulmonal congestion and orthopnea 
were independent predictors of the diagnosis of HF,14-16 while in our study NYHA class and 
several co-morbidities (COPD/asthma, anaemia, renal dysfunction) were the most power-
ful predictors (table 2). This difference could be explained by the difference in clinical 
setting. All patients in the present study were admitted with suspected HF and  therefore 
almost all patients had evidence of cardiac disease. In contrast, about half of the patients in 
the other studies did not have HF at all. A remarkable finding of the present study is that the 
haemoglobin plasma levels were lower in the patients with other discharge diagnoses. The 
fact that anaemia causes symptoms similar to HF, notably dyspnoea and fatigue14 may have 
led to a, suspected, diagnosis of HF at admission. A similar phenomenon is known from 
patients with COPD and also shown in our data.13 
The well established emergency department BNP rule out value of 100 pg/ml and the 
NT-proBNP rule out value of 300 pg/ml were univariable predictors of the discharge diag-
nosis HF, but in multivariable analysis only NT-proBNP > 300 pg/ml remained a statisti-
cally significant determinant. Our results for NT-proBNP confirm the findings from a recent 
study by Baggish et al. who developed  a score for the diagnosis of HF in an acute HF setting 
that included elevated NT-proBNP.15 
The reference (‘gold’) standard that was used in the present study to classify the dis-
charge diagnosis is not perfect due to subjectivity. However, an outcome panel is a common 
way to classify the definite diagnosis and it has been used in many other diagnostic studies, 
including many in the field of heart failure.4,5,16 Furthermore, according to the Standards 
for Reporting of Diagnostic Accuracy (STARD) initiative, a consensus panel is the best proxy 
reference in the absence of an ideal standard.17 Although by bootstrapping the final model 
we adjusted the model for over-fitting, this final model and the points score needs to be 
validated externally in a new sample of patients that is about to be discharged from the 
hospital after admission for suspected HF.
We observed high positive predictive values and low negative predictive values for our 
score categories, which indicates that this score is more a test to confirm the discharge 
diagnosis HF than to reject it. In case of local availability of BNP instead of NT-proBNP, 
the score can be adjusted, although, as mentioned above, the performance of the model 
including BNP (ROC area 0.76) is worse than for the model including NT-proBNP (ROC 
area 0.78)  The corresponding score for BNP is:  absence of anaemia 2 points, NYHA class 
IV 4 points, absence of COPD/ asthma 2 points, renal dysfunction 3 points and BNP > 100 
pg/ml 3 points. 
We conclude that a limited number of readily obtainable data from physical examination 
or medical history (dyspnoea at rest and absence of COPD/asthma) together with renal 
dysfunction, and absence of anaemia and the NT-proBNP value > 300 pg/ml may improve 
the assessment of the discharge diagnosis of patients admitted with suspected HF, and thus 
optimize therapeutic interventions in these patients after discharge. Although we internally 
validated the score by means of bootstrapping, it needs  to be validated externally in a new 
sample of patients that is about to be discharged from the hospital after admission for sus-
pected HF, before it can be recommended for clinical practice. Discharge diagnosis with NT-proBNP
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Abstract
Background: In acute heart failure (HF) patients presenting at the emergency department, 
a BNP < 100 pg/ml was found in only 10% of the patients. However, in a more stable 
outpatient HF population from another study, a BNP < 100 pg/ml was found in as many 
as 21% of the patients. Therefore, we aimed to investigate the prevalence and characteristics 
of stabilized patients with B-type Natriuretic Peptide (BNP) < 100 pg/ml before discharge 
after admission for decompensated HF.
Methods: We investigated 601 HF patients who were part of a large-scale multicenter study 
in the Netherlands. All patients had been admitted for decompensated HF, and BNP levels 
were measured before discharge, when they had been clinically stabilized. Clinical charac-
teristics of patients with BNP levels < and ≥ 100 pg/ml were compared. 
Results: Patients were 70 ±12 years old, 61% was male and mean left ventricular ejection 
fraction (LVEF) was 0.34 ±0.14. Of these patients 10% had BNP levels < 100 pg/ml.  Pa-
tients with a BNP < 100 pg/ml were similar in terms of age and gender, but had higher 
LVEF (0.41 ±0.14 versus 0.33 ±0.13, P<0.001), body mass index, hemoglobin and hema-
tocrit concentrations compared to those with BNP levels ≥ 100 pg/ml. 
Conclusions: In clinically stable patients with a recent admission for decompensated HF, 
only 10% had BNP levels below 100 pg/ml. These patients with low BNP levels seemed 
to have less severe HF and more frequently had preserved systolic function compared to 
patients with BNP levels ≥ 100 pg/ml.
Introduction
B-type Natriuretic Peptide (BNP) is increasingly used in the diagnosis and prognosis of 
heart failure (HF).1-3 In addition, BNP can be used as a discharge criterion and to monitor 
treatment.4, 5 A BNP value of 100 pg/ml is considered the optimal value in the diagnosis or 
exclusion of HF in acute dyspneic patients at the emergency department.2 In these patients 
a BNP cut-off value of 100 pg/ml had a sensitivity of 90%, which means that only 10% of 
HF patients had BNP plasma levels < 100 pg/ml. When the same cut-off value was used 
in a stable outpatient systolic HF population, classified as NYHA functional class II-III, as 
many as 21% of patients had BNP levels below 100 pg/ml,6 which might suggest that the 
prevalence of patients with BNP levels below this cut-off value is much higher than 10% in 
stable HF patients at discharge. However, the prevalence of BNP levels < 100pg/ml in clini-
cally stable hospitalized patients remains unknown. Hence, we investigated the prevalence 
and characteristics of patients with BNP levels < 100 pg/ml classified in NYHA class II-IV, 
before discharge after admission for HF. 
Methods
Study population 
All patients were included in a multicenter HF trial conducted in the Netherlands (Coordi-
nating study evaluating Outcomes of Advising and Counseling in Heart failure [COACH]).7 Prevalence BNP < 100 pg/ml after hospitalisation
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All these sites (n = 17) were experienced HF centers. Patients were included in COACH 
if they were admitted for decompensated HF (NYHA II-IV), with HF as the primary diag-
nosis. Furthermore, patients were required to have evidence of structural underlying heart 
disease, and had to be at least 18 years of age. Reasons for exclusion were: concurrent inclu-
sion in a study requiring additional visits to research health care personnel; restrictions that 
make the patient unable to fill in the data collection forms; invasive intervention within the 
last 6 months (PTCA, CABG, HTX, valve replacement) or planned during the following 3 
months; ongoing evaluation for heart transplantation. The design of the study has been de-
scribed in detail elsewhere.7 In short, COACH is a randomized controlled trial investigating 
the effect of education and counseling on readmission for HF and mortality. Of the 1050 
patients included in the COACH, 601 patients had BNP plasma levels available at baseline. 
Main reasons for missing BNP data were: no Triage® BNP meter available (in 5 out of 17 
clinics; n = 324), unplanned hospital discharge (n = 75) or death during admission (n = 
20). No BNP levels were available at admission, and the investigators and patients of the 
present study were blinded to BNP results at discharge. 
The study was approved by a central Ethical Committee, and all patients provided in-
formed written consent.
BNP measurement 
Blood was collected before discharge between 8:00 AM and 4:00 PM, after patients had 
been clinically stabilized and were recovered well enough to go home. All patients went 
home at the planned day of discharge. Five milliliter of whole blood was taken from an 
antecubital vein and collected into tubes containing potassium ethylenediaminetetraacetic 
acid (EDTA; 1 mg/ml blood) when patients were in a supine position. Within 4 hours after 
blood collection BNP plasma levels were determined using a fluorescence immunoassay 
kit (Triage®, Biosite Incorporated, San Diego, CA). Details on the system provided by the 
manufacturer indicated the analytical sensitivity of the assay is less than 5.0 pg/ml. The 
system has been validated in early studies.8,9  The measurable range of the BNP assays was 
5.0- 5000.0 pg/ml. 
Renal function 
Serum creatinine was determined from the blood draw before discharge, in the local 
laboratory at each center. Estimated Glomerular Filtration Rates (eGFR’s) were calculated 
using the Levey – modified Modification of Diet in Renal Disease formula:10
GFR (ml/min/1.73m2) = 186 x SCr-1.154 x age-0.203 x (0.742 if female) x (1.210 if black) 
Additional demographic and clinical data were collected by chart review. 
Statistical analysis
Differences in clinical characteristics between patients with BNP plasma levels < and ≥ 
100 pg/ml were tested using the Mann-Whitney U test or independent samples t-tests. 
Outcomes were considered statistically significant when P<0.05. Values are presented as 
means ± SD except when stated otherwise.Chapter 7
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Table 1: Patient characteristics divided by BNP levels.
Total
(n=601)
BNP<100 
pg/ml (n=60)
BNP≥100 pg/ml 
(n=541)
P-value
Age (yrs)         70 ± 12   69 ± 11      70 ± 12 0.29
Gender (m) 61% 58% 61% 0.65
Heart failure cause 
  Ischemic 38% 30% 39% 0.18
  Non-ischemic 62% 70% 61% 0.18
LVEF                 0.34 ± 0.14   0.41 ± 0.14            0.33 ± 0.13 <0.001
Co-morbidities 
  Hypertension 34% 47% 33% 0.03
  COPD/Asthma 28% 30% 28% 0.71
  Diabetes (type1 or 2) 28% 27% 28% 0.84
  Renal diseases 7% 7% 7% 1.00
  BMI (kg/m2) 26      ±          5 30 ± 6 26      ± 5 <0.001
X-thorax during admission
  Pulmonal congestion  69% 57% 70% 0.04
  CT-ratio (n=158)                     0.56 ± 0.08      0.53 ± 0.15    0.57 ± 0.06 0.05
Rales during admission 87% 89% 87% 0.76
Duration of HF symptoms (yrs)                   2.7 ± 4.2   2.7 ± 4.0   2.7 ± 4.2 0.93
Duration HF admission (days)           13 ± 11   13 ± 8   13 ± 11 0.55
Medication at admission
  Diuretics 57% 63% 56% 0.29
  ACE/ARB 52% 60% 51% 0.19
  Beta-blockers 39% 38% 39% 0.96
  Spironolacton 16% 22% 15% 0.18
Medication at discharge
  Diuretics 95% 92% 95% 0.21
  ACE/ARB 84% 83% 84% 0.94
  Beta-blockers 61% 48% 63% 0.03
  Spironolacton 50% 50% 50% 0.97
ECG measurements at discharge
  Sinus rhythm 56% 67% 55% 0.08
  AF/flutter 34% 30% 35% 0.48
  HR (bpm)           74 ± 13  76 ± 13  74 ± 13 0.42
Laboratory values at discharge
 BNP (median [interquartile   
range], pg/ml) 
492 (223-952) 55 (37-79) 530 (294-1060) <0.001
  Hb (mmol/l)           8.2 ± 1.2     9.0 ± 1.1  8.2 ± 1.1 <0.001
  Ht (1/l)           0.40 ± 0.05   0.43 ± 0.05  0.40 ± 0.05 <0.01
  eGFR(ml/min1.73m2)             56 ± 21   57 ± 18       55 ± 22 0.56
Blood pressure at discharge (mm/Hg)
  Systolic 119 ± 22 124 ± 22   118 ± 21 0.05
  Diastolic   69 ± 12      73 ± 13    68 ± 12 0.03
  Pulse pressure         50 ± 17   51 ± 17    50 ± 17 0.48
NYHA at admission (II, III, IV) 6%, 53%, 41% 2%, 68%, 30% 7%, 51%, 42% 0.23
NYHA at discharge (II, III, IV) 52%, 45%, 3% 48%, 50%, 2% 53%, 44%, 3% 0.62Prevalence BNP < 100 pg/ml after hospitalisation
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Results
Study population 
Demographic and clinical characteristics of the 601 discharged patients are presented in 
table 1. Mean age of the patients was 70 (± 12) years, and more than half of the popula-
tion was male (61%) and had a non-ischemic etiology for HF (62%). At admission patients 
were classified as NYHA functional class II (6%), III (53%) or IV (41%), and were on 
medical therapy including diuretics (57%), ACE inhibitors/ angiotensin receptor block-
ers (52%), beta-blockers (39%) and spironolactone (16%). At discharge, patients were 
classified as NYHA functional class II (52%), III (45%) or IV (3%), and were on medical 
therapy including diuretics (95%), ACE inhibitors/ angiotensin receptor blockers (84%), 
beta-blockers (61%) and spironolactone (50%). 
Prevalence of low BNP levels at discharge after HF hospitalization 
Of the 601 HF patients, 60 patients (10%) had BNP plasma levels below 100 pg/ml.  Out 
of these 60 patients, 44 patients (7% of the total population) and 28 patients (5% of the 
total population) had BNP levels below 75 pg/ml and 50 pg/ml respectively (figure 1). 
Comparison of patients with BNP < and ≥ 100 pg/ml
The median and interquartile range of BNP values in the group of patients with BNP < 
and ≥ 100 pg/ml were 55 (37-79) and 530 (294-1060) respectively (table 1). Patients 
with BNP levels below 100 pg/ml showed less pulmonary congestion during hospital 
admission compared to patients with high BNP levels (57% vs. 70% respectively; P=0.04). 
At discharge these patients had a significantly higher LVEF (0.41 ± 0.14 vs. 0.33 ± 0.13; 
P<0.001) and diastolic blood pressure (73 ± 13 mmHg vs. 68 ± 12 mmHg; P=0.02), and 
a significantly higher prevalence of hypertension (47% vs. 33%; P=0.02) than patients with 
BNP levels ≥ 100 pg/ml. Furthermore, at discharge body mass index (30 ± 6 vs. 26 ± 5; 
P<0.001), hemoglobin (9.0 ± 1.1 vs. 8.2 ± 1.1; P<0.001) and hematocrit (0.43 ± 0.05 
vs. 0.40 ± 0.05; P<0.01) were significantly higher in patients with low BNP levels com-
pared to patients with high BNP levels. Moreover, patients with low BNP levels less often 
had received beta-blockers at discharge (48% vs. 63%; P=0.03) compared to patients with 
high BNP levels. Other variables were not significantly different between the two groups 
(table1).
Legend table 1: ACE/ARB= ACE inhibitor or Angiotensin Receptor Blocker, AF= Atrial Fibrillation, BMI= Body 
Mass Index, BNP= B-type Natriuretic Peptide, COPD= Chronic Obstructive Pulmonary Disease, CT-ratio= 
Cardio- Thoracic ratio, eGFR= estimated Glomerular Filtration Rate, Hb= Hemoglobin, HF= Heart Failure, 
HR= Heart Rate, Ht= Hematocryte, LVEF= Left Ventricular Ejection Fraction, NYHA= New York Heart As-
sociation functional class.Chapter 7
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Discussion
The major finding of the present study is that only 10% of clinically stabilized hospitalized 
HF patients had pre-discharge BNP plasma levels below 100 pg/ml.
In patients with acute dyspnea, Maisel et al. showed a sensitivity of 90% for a BNP cut-off 
value of 100 pg/ml to diagnose HF,2 and Morrison and colleagues showed a sensitivity of 
86% for a BNP value of 94 pg/ml to differentiate HF from pulmonary disease.11 In other 
words, in these studies 10% and 14% of HF patients had BNP plasma levels below 100 
pg/ml and 94 pg/ml respectively. 
In an outpatient clinic setting Tang and co-workers found that as much as 21% of 
chronic symptomatic systolic HF patients had BNP levels below 100 pg/ml.6 Recently, a 
low prevalence of low BNP levels was shown in a systematic review that mainly described 
studies on acute dyspnea and outpatient clinic HF patients. However, the majority of the 
studies described in this review showed the highest diagnostic accuracy to differentiate 
between dyspnea due to HF and dyspnea due to other pathology for a cut-off value of 52 
pg/ml.12 Since BNP is related to the severity of HF,13 it is conceivable that BNP plasma levels 
are higher in HF patients during acute dyspnea compared to an outpatient clinic setting. In 
addition, BNP levels are probably higher in acute dyspneic HF patients compared to ‘dry 
BNP levels’ in stabilized HF patients.14 Therefore, the 10% of HF patients with BNP levels 
below 100 pg/ml that were found in the present study, is lower than expected based on 
previous literature.14 When the cut off values of 75 pg/ml and 50 pg/ml were used, 7% and 
BNP values (pg/ml)
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Figure 1: BNP plasma levels (n=601). 
BNP = B-type natriuretic peptide, N = number of patients.Prevalence BNP < 100 pg/ml after hospitalisation
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5% of the patients were found to have BNP levels below these cut-off values respectively. This 
finding shows that within the group of patients with BNP < 100 pg/ml the distribution of 
BNP levels was normal, indicating that in this group no majority exists with ‘healthy’ BNP 
levels of < 20 pg/ml.15
Tang et al. showed that patients with BNP < 100 pg/ml were more likely to be younger, 
to be female, and to have a non-ischemic etiology, better-preserved cardiac and renal func-
tion, and less atrial fibrillation as compared to patients with BNP > 100 pg/ml.6 The same 
differences between the groups were found in the present study (table 1), although of these 
variables only LVEF was statistically significant. This indicates a specific profile of patients 
with BNP plasma levels < 100 pg/ml. The differences between patients with high and low 
BNP levels in current population, suggest that patients with BNP < 100 pg/ml had less 
severe HF, and more often had HF with preserved systolic function.
Moreover, we found significantly higher body mass indexes in the low BNP group, con-
firming data recently published which have shown that obesity is related to lower BNP 
values.16,17 There are two explanations for this consistent finding. First, natriuretic peptide 
clearance receptors (NPR-C) are abundant in adipose tissue, suggesting that adipocytes 
participate in the removal of natriuretic peptides from the circulation.18 A second explana-
tion of lower BNP plasma levels in obese patients may be an impaired natriuretic peptide 
secretion. In isolated obese Zucker rat hearts, an impaired signal cascade myocardial protein 
kinase C - MAP kinase - natriuretic peptide secretion was shown, as compared to lean rat 
hearts.19 In another study in young, healthy, normotensive obese subjects, an impaired na-
triuretic peptide secretion was shown in response to saline load.20
Logeart et al. showed that patients with a decrease in BNP plasma levels during HF ad-
mission had a lower risk on events after discharge compared to patients with unchanged 
or increased BNP levels during admission.21 Therefore, the authors recommend a ‘decrease 
of BNP approach’ for clinical practice. The present results, however, indicate that a goal 
of decreasing BNP levels during HF admission below 100 pg/ml is not realistic for most 
patients. 
Altogether, the 10% of heart failure patients that were found to have low BNP levels at 
discharge in the present study is a remarkably low percentage, when taken into account 
that 21% of stable outpatient clinic patients had low BNP levels. This finding adds value to 
the use of BNP in clinical practice in patients recently admitted for HF, and extends the low 
prevalence of normal BNP levels from acute dyspneic patients2 to stabilized in hospital HF 
patients. 
Limitations
The present study was limited by its cross sectional design. BNP plasma levels at hospital 
admission and post discharge outcomes would have added to the importance of the study. 
However, an evaluation of the BNP value of 100 pg/m at hospital discharge, adds important 
knowledge for clinical practice, since this value is increasingly used.
Conclusion
The present study demonstrated that 10% of patients with a recent admission for decom-
pensated HF have BNP plasma levels 100 pg/ml. These patients seem to have less severe HF 
and more often have HF with preserved systolic function. Chapter 7
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BNP/ NT-proBNP in heart failure: the holy grail in clinical 
practice? 
After the publication of a large number of studies on the potential beneficial effects of 
BNP and NT-proBNP in the diagnosis and prognosis of HF, as well enthusiasm about the 
possible value of BNP/NT-proBNP guided therapy, many physicians have started to use na-
triuretic peptides in clinical practice. Many questions regarding the application of BNP/NT-
proBNP in daily practice, however, have remained unanswered. These include:
-    Are BNP and NT-proBNP only elevated in case of HF, or are there other clinical condi-
tions involved that cause elevated plasma levels? In other words, which clinical condi-
tions other than severity of HF are related to BNP and/or NT-proBNP plasma levels? 
-    Since BNP/ NT-proBNP may be related to age and gender in HF patients, should cut-off 
values be age and gender specific? 
-    Which one, BNP or NT-proBNP should be preferred in daily clinical practice? 
-    Are BNP and NT-proBNP also useful in conditions other than in the differentiation 
between cardiac and pulmonary dyspnoea at the emergency department? 
-    Are the cut-off values established in studies in the emergency department setting also 
valuable at discharge after admission for HF?
-    Is BNP/NT-proBNP really useful in the titration of HF medication? 
The major findings from the studies presented in this thesis include:
-  In HF patients elevated BNP/NT-proBNP levels are clearly associated with increasing age.
-  Anaemia and renal dysfunction are related to increased BNP and NT-proBNP levels, 
independent of the severity of HF. 
-  Renal dysfunction is relatively stronger related to elevated NT-proBNP levels than to 
elevated BNP levels.
-  BNP is not related to physical dimensions of quality of life, nor to sub maximal func-
tional capacity in HF patients.
-  Dyspnoea at rest, absence of COPD/Asthma, renal dysfunction, absence of anaemia 
and NT-proBNP > 300 pg/ml are independent predictors of a discharge diagnosis HF.   
These five simple diagnostic predictors were transformed in a scoring rule (range 0 
- 14) that can be applied in daily practice.
-  10% of the patients admitted with suspected HF have BNP levels below the well estab-
lished BNP cut-off value of 100 pg/ml at discharge. 
Thus, the studies provided useful information pertaining to the remaining questions 
mentioned above. Below, several of these issues will discussed in more detail in the context 
of the total body of evidence and suggestions for future studies are given.   General discussion
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Single cut off values for BNP and NT-proBNP or should cut off values depend on patient 
characteristics?
Until now, a single BNP cut-off value to differentiate between a cardiac and pulmonary 
cause of dyspnoea has been proposed for all patients (100 pg/ml). For NT-proBNP however, 
both non-stratified and age specific cut-off values have been advocated. In this thesis we 
showed that BNP and NT-proBNP are not only independently related to age, but also to 
renal dysfunction and anaemia. Moreover, previous research showed that both BNP and 
NT-proBNP levels are depressed in case of an elevated body mass index.1-3 Thus, it could 
be argued that one should adjust the BNP and NT-proBNP threshold indicating abnormal 
levels to important influencing factors such as age, renal function, anaemia and body mass 
index.
Previous research showed that both BNP and NT-proBNP levels are related to age and gen-
der in healthy subjects .4 In addition, we showed that BNP and NT-proBNP are also related 
to age in HF patients. The difference between males and females was less pronounced in 
our study population than in healthy subjects. This finding implicates that only age and not 
gender should be taken into consideration when interpreting BNP and NT-proBNP results 
in HF patients. Nevertheless, the correlations between BNP/ NT-proBNP and age were only 
moderate and comparable to other factors, indicating that it is not necessary to use age 
specific thresholds. Furthermore, stratification of cut-off values according to age could be 
problematic because BNP levels are lower in patients with diastolic HF than systolic HF.  5 
Consequently, diastolic HF, which is most prevalent in the elderly, will be missed more 
frequently when these cut-off values are higher for elderly patients. 
Since we showed that both BNP and NT-proBNP, are independently associated to anaemia 
and renal dysfunction, it is important to take these clinical conditions into consideration 
when interpreting natriuretic peptide plasma levels. Does this also mean that we should 
adjust BNP/NT-proBNP cut-off values in case these conditions are present? Several inves-
tigators studied the influence of renal function on optimal cut-off values, with varying 
findings. Four studies in patients with acute dyspnoea at the emergency department6,7 and 
in patients with a history of myocardial infarction8,9 found that renal dysfunction stratified 
cut-off values showed better diagnostic accuracy than a single cut-off value. In contrast, 
Anwaruddin et al. did not find a significant difference between renal function adjusted and 
non-adjusted NT-proBNP cut-off values in dyspnoeic patients with suspected HF. Other 
studies showed an inverse effect of anaemia on BNP levels in patients without HF10-12 and of 
anaemia on NT-proBNP in a small group of HF patients.13  To our knowledge, our study was 
the first to investigate both relations in one large group of HF patients. Since we found that 
both BNP and NT-proBNP are higher in anaemic compared to non-anaemic HF patients, the 
stratification question arises again. 
Since, BNP and NT-proBNP are associated to both age and several clinical conditions (apart 
from anaemia, renal dysfunction and body mass index, natriuretic levels have also been re-
ported to be increased in e.g. COPD patients) it is not useful, if doable at all, to apply specific 
cut-off values for all of these factors. In addition, the applicability of BNP/NT-proBNP assess-Chapter 8
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ments is hampered when thresholds differ across relevant patient categories. We therefore 
recommend to use single cut-off values in clinical practice, and neither stratify for age, 
nor for renal function, haemoglobin levels or body mass index, and interpret BNP and 
NT-proBNP levels in conjunction with the complete clinical assessment of HF patients in 
clinical practice.
Another implication for clinical practice of our results may be that in some clinical situ-
ations it may be wiser to primarily evaluate a patient on the basis of signs and not on the 
basis of BNP/ NT-proBNP levels. For example, in case of an elderly patient with renal dys-
function and anaemia it is hard to establish whether the elevated natriuretic peptide levels 
reflect severity of HF or only the severity of his or her co-morbidities. 
Undoubtedly, BNP/NT-proBNP are not the miracle predictors of the physical and mental 
status of HF patients some researchers believe it to be. We, for example, also demonstrated 
that BNP does not reflect physical dimensions of quality of life, an important target for HF 
therapy. Our results confirmed the findings of Luther et al. who showed that BNP was not 
related to health status as measured by the Kansas City Cardiomyopathy Questionnaire.14 
This instrument measured symptoms, physical function, social function, self efficacy and 
quality of life. In addition we found that BNP was not related to 6-minute walk test (sub 
maximal functional capacity), a measure that reflects daily activities of elderly patients. For 
clinical practice, we suggest that quality of life and sub maximal functional capacity should 
be measured in addition to BNP and the currently available diagnostic tools.
When should BNP/ NT-proBNP be used?
There is strong supportive evidence for the use of BNP and NT-proBNP in an emergency 
department setting in differentiating cardiac from pulmonary dyspnoea.15,16 Additionally, 
we showed that together with readily available clinical variables such as the severity of 
HF symptoms at admission (NYHA class IV), the absence of COPD, renal dysfunction and 
absence of anaemia, a NT-proBNP level exceeding > 300 pg/ml is and independent de-
terminant of the discharge diagnosis HF in patients admitted with suspected HF. Based 
on these diagnostic predictors we constructed a diagnostic score that could be applied in 
clinical practice, albeit that external validation is needed before its use on a larger scale can 
be recommended. When instead of an NT-proBNP assay, a BNP assay is locally available, the 
score can be adjusted. 
We also studied the value of established cut-off values of BNP at discharge after admission 
for HF. Earlier studies  showed that 10%16 and 21-30%17,18 of acute dyspnoeic and stable 
HF patients respectively, had BNP levels below the established threshold of 100 pg/ml. 
Furthermore, Knebel et al. showed that a decrease in BNP levels during admission was ac-
companied by recompensation of HF patients that were admitted to the hospital for decom-
pensated HF. Based on these results one might expect that the percentage of false positive 
results would be higher in HF patients that are recompensated after hospital admission than 
in decompensated HF patients. However, we found that when using the established BNP 
cut-off value at discharge, the proportion of false positive HF diagnoses was equal to the 
proportion in patients with BNP levels below this cut-off value at the emergency depart-General discussion
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ment (10%). This result indicates that this BNP cut-off value may be useful at discharge 
after admission for suspected HF. Since we showed that patients with natriuretic peptide 
plasma levels below the threshold had less severe HF and a preserved systolic function, 
the cut-off values can possibly be used at discharge after admission for HF for purposes 
of differentiation between patients with severe and less severe HF and between preserved 
and suppressed systolic function. This information may give an indication as to whether 
a patient requires more intensive medical treatment or a more intensive post discharge 
follow up scheme. 
Should we use either BNP or NT-proBNP (or both?) in clinical practice?
It is hard to give a straightforward answer to the question whether BNP or NT-proBNP 
should be preferred in clinical practice since both peptides have similar benefits (diagnos-
tic properties in suspected HF) and limitations (influenced by several clinical conditions/ 
co-morbidities other than HF). A disadvantage of BNP is its stronger relationship to age 
and a disadvantage of NT-proBNP is that it is more strongly related to renal dysfunction. 
The preferential use of BNP or NT-proBNP should ideally be based on its clinical purpose 
(i.e. diagnosis, prognosis or intensive or less-stringent monitoring of therapy), since the 
most important difference between the two is their half life in blood (20 minutes vs. 120 
minutes respectively). For diagnostic and prognostic purposes the two are comparable, 
even if patient characteristics differentially influence BNP or NT-pro BNP levels, as outlined 
above. When the aim is to monitor more gradual changes in HF severity over a longer time 
period, NT-proBNP may be more useful and when quick changes in HF severity should be 
detected, BNP may be preferred. Furthermore, there are practical issues that are important 
in the decision to prefer one of the two markers in clinical practice. For example, the Bi-
osite Triage BNP meter is a bedsite meter and the Roche Elecsys NT-proBNP meter is a full 
automatic laboratory meter. In some situations, a clinician may not have a choice between 
BNP and NT-proBNP because a laboratory already chose either one of them based on their 
preferences.
In view of the current available literature, the use of both BNP and NT-proBNP has no 
additional value for clinical practice.19  
Future perspectives
Clearance of BNP/NT-proBNP
The differences between BNP and NT-proBNP in their association with renal function 
could be explained in different ways. On the one hand McCullough et al. found that stron-
ger influence of renal function on NT-proBNP may be attributable to differences in clear-
ance. They postulate that in contrast to the renal clearance of NT-proBNP, BNP is mainly 
cleared from the bloodstream by natriuretic peptide clearance receptors and by neuro en-
dopeptidases. On the other hand, the observed differences between BNP and NT-proBNP 
are moderate, and this is considered a reflection of structural heart disease and as ‘cardio-
renal’ interaction.20  Two small studies in healthy young men and in hypertensive patients 
showed that about 20% of both BNP and NT-proBNP are cleared from the bloodstream by 
the kidneys.21,22 This, however, has never been confirmed in a large group of HF patients. Chapter 8
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In addition, studies applying micro punction of the efferent and afferent renal arterioles 
are lacking. By using this method, an exact change in NT-proBNP levels caused by renal 
filtration can be determined. 
Urine BNP/ NT-proBNP guided treatment
There are indications that NT-proBNP guided treatment may be of additional value in 
the management of HF.23 Since plasma levels of NT-proBNP are influenced by many patient 
characteristics, including co-morbidity, as well as by biological variation, the use of NT-
proBNP levels for guidance of HF treatment may be limited due to fluctuations caused by 
other phenomena than worsening HF.
Since a fraction of NT-proBNP is cleared from the blood by the kidneys, NT-proBNP may 
also be detected in urine of HF patients. In a study on screening for left ventricular systolic 
dysfunction Ng et al. showed that NT-proBNP can be detected in urine.24 NT-proBNP in 
urine could also be used for guidance of medical treatment. Ideally, this would require ac-
curate NT-proBNP values without fluctuations due to reasons other than worsening HF. In 
24 hours urine, an average NT-proBNP value in an individual HF patient on a particularly 
day, without daily variation, could serve as an indicator of the appropriateness of medi-
cal therapy. However, it is known that peptides such as NT-proBNP are broken down in 
the proximal renal tubule, but it is unknown whether the proportion that is cleared by 
the kidneys differs according the concentrations of plasma NT-proBNP. Therefore, data on 
the relationship between plasma NT-proBNP and urine NT-proBNP in HF patients with 
and without renal dysfunction are needed before trials on urinary NT-proBNP guided HF 
therapy can be initiated.
Other options of titration medical treatment
As already stated before, there are indications that NT-proBNP guided HF therapy results 
in lower mortality and fewer hospitalizations than clinical monitoring alone. Larger tri-
als are underway that are about to either confirm or reject these pilot results. In addition, 
other ways to guide medical treatment have been proposed. Pilot studies showed that blood 
volume change or impedance cardiography may be good candidate markers for this pur-
pose.25,26 Firmer studies are necessary to asses which of these methods could be applied to 
monitor HF treatment. 
Multivariable prognosis
Until now, only the univariable prognostic value of BNP and NT-proBNP levels, and a 
multivariable risk score without BNP or NT-proBNP levels27 have been published. A multi-
variable risk score including data readily obtainable from physical examination and medical 
history as well as BNP or NT-proBNP levels could improve the identification of HF patients 
at increased risk for future cardiovascular events. An optimal risk stratification for HF pa-
tients is important to optimize (dosages of) HF medication and the intensity of medical 
follow up.General discussion
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Conclusion
BNP and NT-proBNP have important benefits in the daily management of patients with 
possible or established HF, including, as shown in this thesis, those patients discharged 
from hospital after admission for suspected HF. Besides the benefits, however, our studies 
also revealed important limitations that should be taken into consideration in the decision 
to assess BNP/ NT-proBNP levels and in the interpretation of the test results. Chapter 8
112
References
1  Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, Canham RM, Chung AK, Leonard 
D, Wians FH Jr, de Lemos JA. Impact of body mass and body composition on circulating levels of 
natriuretic peptides: results from the Dallas Heart Study. Circulation 2005;112:2163-8.
2  Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, Frohlich ED. Obesity and suppressed 
B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590-5.
3  Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma 
natriuretic peptide levels. Circulation 2004;109:594-600.
4  Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J Pedersen F. The influ-
ence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in 
a large sample of the general population. Heart 2003;89:745-51.
5  Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy 
P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Knudsen CW, Perez A, Kamin R, Ka-
zanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. 
Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or pre-
served ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 
2003;41:2010-7.
6  Chenevier-Gobeaux C, Claessens YE, Voyer S, Desmoulins D, Ekindjian OG. Influence of renal function 
on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the 
Emergency Department: Comparison with brain natriuretic peptide (BNP). Clin Chim Acta 2005;361:167-
75.
7  McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, West-
heim A, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy 
P, Kazanegra R, Maisel AS; Breathing Not Properly Multinational Study Investigators. B-type natriuretic 
peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly 
Multinational Study. Am J Kidney Dis 2003;41:571-9.
8  Luchner A, Hengstenberg C, Lowel H, Trawinski J, Baumann M, Riegger GA, Schunkert H, Holmer S. 
N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. 
Hypertension 2002;39:99-104.
9  Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Holmer S. Effect of compensated renal 
dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) 
and N-terminal pro-BNP. Hypertension 2005;46:118-23.
10  Tsuji H, Nishino N, Kimura Y, Yamada K, Nukui M, Yamamoto S, Iwasaka T, Takahashi H. Haemoglobin 
level influences plasma brain natriuretic peptide concentration. Acta Cardiol 2004;59:527-31.
11  Willis MS, Lee ES, Grenache DG. Effect of anemia on plasma concentrations of NT-proBNP. Clin Chim 
Acta 2005;358:175-81.
12  Wold KC, Vik-Mo H, Omland T. Blood haemoglobin is an independent predictor of B-type natriuretic 
peptide (BNP). Clin Sci (Lond) 2005;109:69-74.
13  Wu AH, Omland T, Wold KC, McCord J, Nowak RM, Hollander JE, Duc P, Storrow AB, Abraham WT, 
Clopton P, Maisel AS, McCullough PA. Relationship of B-type natriuretic peptide and anemia in pa-
tients with and without heart failure: A substudy from the Breathing Not Properly (BNP) Multinational 
Study. Am J Hematol 2005;80:174-80.General discussion
113
14  Luther SA, McCullough PA, Havranek EP, Rumsfeld JS, Jones PG, Heidenreich PA, Peterson ED, Rathore 
SS, Krumholz HM, Weintraub WS, Spertus JA, Masoudi FA. The relationship between B-type natriuretic 
peptide and health status in patients with heart failure. J Card Fail 2005;11:414-21.
15  Januzzi JL, van KR, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards 
M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an 
international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur 
Heart J 2006;27:330-7.
16  Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Ab-
raham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann 
HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Rapid measurement of 
B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-7.
17  Tang WH, Girod JP, Lee MJ, Starling RC, Young JB, Van Lente F, Francis GS. Plasma B-type natriuretic 
peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Cir-
culation 2003;108:2964-6. 
18  Hulsmann M, Berger R, Mortl D, Gore O, Meyer B, Pacher R. Incidence of normal values of natriuretic 
peptides in patients with chronic heart failure and impact on survival: a direct comparison of N-termi-
nal atrial natriuretic peptide, N-terminal brain natriuretic peptide and brain natriuretic peptide. Eur J 
Heart Fail 2005;7:552-6.
19  Pfister, R. and C. A. Schneider. “Natriuretic peptides BNP and NT-pro-BNP: established laboratory 
markers in clinical practice or just perspectives?” Clin Chim Acta 2004;349:25-38.
20  Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi JL Jr. Renal 
function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: re-
sults from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am 
Coll Cardiol 2006;47:91-7.
21  Schou M, Dalsgaard MK, Clemmesen O, Dawson EA, Yoshiga CC, Nielsen HB, Gustafsson F, Hilde-
brandt PR, Secher NH. Kidneys extract BNP and NT-proBNP in healthy young men. J Appl Physiol 2005; 
99:1676-80.
22  van Kimmenade RR, Bakker JA, Houben AJ, Kroon AA, Rennenberg R, Crijns HJ, van Dieijen-Visser MP, 
de Leeuw PW, Pinto YM. Renal Handling of BNP and NT-proBNP in Hypertensive Subjects. AHA 2005, 
abstract 2843/C165. 
23  Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart 
failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 
2000;355:1126-30.
24  Ng LL, Loke IW, Davies JE, Geeranavar S, Khunti K, Stone MA, Chin DT, Squire IB. Community screening 
for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol 
2005;45:1043-50.
25  James KB, Troughton RW, Feldschuh J, Soltis D, Thomas D, Fouad-Tarazi F. Blood volume and brain 
natriuretic peptide in congestive heart failure: a pilot study. Am Heart J 2005;150:984.
26  Yu CM, Wang L, Chau E, Chan RH, Kong SL, Tang MO, Christensen J, Stadler RW, Lau CP. Intrathoracic 
impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early 
warning preceding hospitalization. Circulation 2005;112:841-8.
27  Kannel WB, D’Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk 
of heart failure. Arch Intern Med 1999;159:1197-1204.Summary116
Summary
The diagnostic and prognostic properties of B-type Natriuretic Peptide (BNP) and N-ter-
minal proBNP (NT-proBNP) in patients with heart failure have been well established dur-
ing the past years. Today, measurement of natriuretic peptides is frequently used in clinical 
practice. However, although very promising, there are several factors that might limit the 
diagnostic and prognostic use of these peptides. This thesis provided a critical appraisal on 
the benefits and limitations of the use of natriuretic peptides in heart failure patients. 
The primary aims of this thesis were: 
1. To assess the influence of age, renal dysfunction, anaemia, functional capacity and 
quality of life on levels of BNP and/or NT-proBNP. 
2. To identify the independent predictors of the discharge diagnosis heart failure, and to 
develop an easy applicable scoring rule using these independent predictors and BNP 
and/or NT-proBNP levels. 
3. To investigate the value of the currently available cut-off value of BNP levels for exclu-
sion of heart failure in a setting of discharge from the hospital after admission for heart 
failure. 
Since most studies on BNP and NT-proBNP have been performed in emergency depart-
ment settings and because only little evidence is available on their usefulness in a setting 
of discharge after admission for heart failure, we studied BNP and NT-proBNP levels in a 
population of patients that were about to be discharged after admission for suspected heart 
failure. We described the criteria of this population, which was included in the COACH 
study, in chapter 2.
In healthy subjects, natriuretic peptide levels are higher with increasing age, but it re-
mained unknown whether the same is true for patients with heart failure. In chapter 3 we 
described that all studied natriuretic peptides were significantly related to age (p<0.05) on 
multivariate regression analysis, with partial correlation coefficients of 0.18, 0.29, 0.28 and 
0.25 for ANP, NT-ANP, BNP and NT-proBNP respectively. The relative increase of both BNP 
and NT-proBNP with age were more pronounced than the relative increase of ANP and NT-
ANP with age (p<0.01). Furthermore, the relative increase of BNP with age was markedly 
larger than of NT-proBNP (p<0.01). Levels of all natriuretic peptides were also significantly 
related to cardiothoracic ratio, renal function and left ventricular ejection fraction. 
Other phenomena that may possibly influence BNP and NT-proBNP levels are anaemia 
(by increasing plasma volume) and renal dysfunction (by decreasing clearance), although 
this was not been well described in heart failure patients. We therefore aimed to study 
the influence of anaemia and renal dysfunction on BNP and NT-proBNP levels in heart 
failure patients. In chapter 4 we showed that in a heart failure population of 541 patients, 
30% (n=159) was anaemic (Hb<7.5 mmol/L for women and Hb<8.1 mmol/L for men). 
Of the 159 anaemic patients, 73% had renal dysfunction (estimated GFR <60 ml/min/
1.73m2) and of the non-anaemic patients, 57% had renal dysfunction. Multivariable analysis 
demonstrated that both plasma haemoglobin and estimated GFR were independently related 
to the level of both BNP and NT-proBNP (standardized beta’s of -0.20, -0.13 [BNP] and 
-0.26, -0.28 [NT-proBNP] respectively, P-values <0.01). Summary
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Both BNP and the 6-minute walk test are related to severity and prognosis of heart failure. 
However, in chapter 5 we did not find a correlation between BNP and the 6-minute walk 
test, indicating that BNP and the 6-minute walk test represented different aspects of the 
clinical syndrome of heart failure (r=0.01, P=0.87). Further results of our study suggested 
that BNP plasma levels were more related to cardiac function, while the 6-minute walk test 
reflected functional capacity and physical dimensions of quality of life. 
Early validation studies showed that 18% - 33% of patients admitted for suspected heart 
failure received a false-positive discharge diagnosis of heart failure. We aimed to identify 
the most important independent predictors of a (false) heart failure discharge diagnosis 
and to construct a score to improve the discharge diagnosis of heart failure (chapter 6). 
The outcome panel that we put together, identified 6% of our research population that was 
admitted for suspected heart failure (n=540) with a discharge diagnosis other than heart 
failure. Univariable predictors of the discharge diagnosis heart failure were dyspnoea at rest, 
absence of COPD/ asthma, absence of anaemia, renal dysfunction, BNP > 100 pg/ml and 
NT-proBNP > 300 pg/ml. In multivariable logistic analyses, all of these, except BNP > 100 
pg/ml, remained independent predictors of a heart failure discharge diagnosis. The ROC 
area of a model combining these predictors was 0.78. These independent predictors were 
combined in a scoring rule to optimize the discharge diagnosis of these patients. This score 
should be validated in other populations before its use in clinical practice can be recom-
mended
Previous studies in acute heart failure patients presenting at the emergency department, 
found a BNP < 100 pg/ml in only 10% of the patients. However, in a more stable outpatient 
heart failure population from another study, a BNP < 100 pg/ml was found in as many as 
21% of the patients. Therefore, we aimed to investigate the prevalence and characteristics of 
stabilized patients with BNP < 100 pg/ml before discharge after admission for heart failure. 
In chapter 7 we showed that in our study population consisting of clinically stable patients 
with a recent admission for heart failure, only 10% had BNP levels below 100 pg/ml. These 
patients with low BNP levels seemed to have less severe heart failure and more frequently 
had preserved systolic function compared to patients with BNP levels ≥ 100 pg/ml.
In chapter 8 we discussed whether different BNP and NT-proBNP cut-off values should 
be used in different populations, since natriuretic peptides are not only influenced by the 
severity of heart failure, but by several other factors as well (this thesis). On the other hand, 
it would be very unpractical to use many different cut-off levels for each group of patients. 
This means that each outcome level of BNP or NT-proBNP should be interpreted in the light 
of the other factors that might have influenced this value. 
We also discussed the issues of whether we should use either BNP or NT-proBNP in clini-
cal practice, and in which settings these natriuretic peptides can be used. Finally we made 
several recommendations for future clinically applied research on BNP and NT-proBNP in 
patients with heart failure.
In conclusion, BNP and NT-proBNP have important benefits in the daily management of 
patients with possible or established heart failure, including, as shown in this thesis, those 
patients discharged from hospital after admission for suspected heart failure. Besides the 
benefits, however, our studies also revealed important limitations that should be taken into 
consideration in the decision to assess BNP/ NT-proBNP levels and in the interpretation of Nederlandse samenvatting120
Samenvatting 
In de diagnose en prognose van hartfalen hebben B-type Natriuretisch Peptide (BNP) en 
N-terminaal proBNP (NT-proBNP) in de afgelopen jaren hun waarde bewezen. Tegenwoor-
dig worden natriuretische peptiden dan ook frequent gebruikt in de klinische praktijk. 
Hoewel het gebruik van deze natriuretische peptiden veelbelovend is, zijn er echter diverse 
factoren die de toepassing bij zowel de diagnose als de prognose van hartfalen kunnen be-
perken. Dit proefschrift leverde een kritische noot over de voor- en nadelen van het gebruik 
van natriuretische peptiden bij patiënten met hartfalen. 
De hoofddoelen van dit proefschrift waren:
1. Het bepalen van de invloed van leeftijd, nierdisfunctie, anemie, functionele capaciteit 
en kwaliteit van leven op BNP en NT-proBNP spiegels.
2. Het identificeren van onafhankelijke predictoren van de ontslagdiagnose hartfalen en 
het ontwikkelen van een eenvoudig toepasbare diagnostische score die deze predictoren 
bevat evenals BNP en/ of NT-proBNP waarden. 
3. Het onderzoeken van de gangbare BNP afkapwaarde om hartfalen uit te sluiten bij ontslag 
uit het ziekenhuis na een opname voor hartfalen.
De meeste studies over BNP en NT-proBNP zijn uitgevoerd op een afdeling Spoedeisende 
Hulp. Er is slechts weinig bewijs voor het gebruik van BNP en NT-proBNP bij ontslag uit 
het ziekenhuis na opname voor hartfalen. Daarom hebben we BNP en NT-proBNP waarden 
onderzocht in een populatie patiënten opgenomen voor verdenking op hartfalen, vlak voor 
ontslag uit het ziekenhuis. We hebben de criteria van deze populatie, die was geïncludeerd 
in de COACH studie, evenals het design van de NHS-COACH studie, beschreven in hoofd-
stuk 2. 
Bij gezonde proefpersonen zijn natriuretische peptiden waarden hoger naarmate de leef-
tijd toeneemt. Tot nu toe was echter onduidelijk of deze leeftijdsafhankelijkheid ook bestaat 
voor patiënten met hartfalen. In hoofdstuk 3 beschreven we dat alle onderzochte natriure-
tische peptiden significant gerelateerd waren met leeftijd (P<0.05) in een multivariabele 
analyse. De partiele correlatiecoëfficiënten waren respectievelijk 0,18; 0,29; 0,28 en 0,25 
voor ANP, NT-ANP, BNP en NT-proBNP. BNP en NT-proBNP namen relatief meer toe met 
leeftijd dan ANP en NT-ANP (P<0,01). Verder nam BNP relatief meer toe met leeftijd dan 
NT-proBNP (P<0,01). Waarden van alle onderzochte natriuretische peptiden waren ook 
significant gerelateerd aan CT-ratio, nierfunctie en linker ventrikel ejectie fractie.
Andere factoren die BNP en NT-proBNP waarden mogelijk kunnen beïnvloeden zijn ane-
mie (via een vergroot plasma volume) en nierdisfunctie (via een verminderde klaring). Dit 
was tot nu toe nog beperkt beschreven in patiënten met hartfalen. In hoofdstuk 4 hebben 
we beschreven wat de invloed is van anemie en nierdisfunctie op BNP en NT-proBNP bij 
patiënten met hartfalen. In een populatie van 541 patiënten met hartfalen lieten we zien dat 
30% (n=159) van de patiënten anemisch was (hemoglobine <7.5 mmol/L voor vrouwen 
en hemoglobine <8.1 mmol/L voor mannen). Van de 159 anemische patiënten had 73% 
nierdisfunctie (geschatte GFR <60 ml/min/1.73m2); van de patiënten zonder anemie had 
57% nierdisfunctie. Multivariaat bleek dat zowel hemoglobine als nierfunctie (geschatte 
GFR) onafhankelijk gerelateerd waren aan BNP en NT-proBNP waarden (gestandaardiseer-Samenvatting
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de beta’s van -0.20, -0.13 [BNP] en -0.26, -0.28 [NT-proBNP] respectievelijk, P-waarden 
<0.01). 
BNP en de 6-minuten looptest (die submaximale functionele capaciteit meet) zijn beide 
gerelateerd aan ernst en prognose van hartfalen. Echter in onze onderzoekspopulatie van 
229 patiënten met hartfalen (70 ± 12 jaar oud en 63% mannen) hebben we geen relatie 
gevonden tussen BNP en 6-minuten looptest (hoofdstuk 5). Dit impliceert dat BNP en 6-
minuten looptest verschillende aspecten van het klinische syndroom van hartfalen weerge-
ven (r=0.01, P=0.87). Verder waren BNP waarden meer met hartfunctie (linker ventrikel 
ejectie fractie) gerelateerd en de 6-minuten looptest hield verband met fysieke componen-
ten van kwaliteit van leven. 
Eerdere onderzoeken naar de juistheid van de ontslagdiagnose hartfalen hebben aange-
toond dat 18% - 33% van de patiënten die waren opgenomen met verdenking op hartfalen 
uiteindelijk toch niet voor hartfalen waren opgenomen. In hoofdstuk 6 beschreven we dat 
in onze populatie slechts 6% van de patiënten die waren opgenomen voor verdenking op 
hartfalen (n=540) een ontslagdiagnose hadden die anders was dan hartfalen. Een goede 
ontslagdiagnose hartfalen werd vaker gesteld bij mensen met dyspnoea in rust, afwezigheid 
van COPD/ astma, afwezigheid van anemie, nierdisfunctie en NT-proBNP > 300 pg/ml. 
De oppervlakte onder de ROC curve van het logistische regressie model met deze multiva-
riabele predictoren was 0.78. Deze onafhankelijke predictoren hebben we gecombineerd 
in een score om de ontslagdiagnose hartfalen te optimaliseren. Deze score zal eerst moeten 
worden gevalideerd in andere populaties voor het gebruik ervan in de klinische praktijk 
kan worden aanbevolen.
In een onderzoek bij patiënten met acuut hartfalen op een afdeling Spoedeisende Hulp 
werd in slechts 10% van de patiënten een BNP < 100 pg/ml gevonden.  In een onderzoek in 
een stabiele hartfalen populatie op een polikliniek werd bij 21% van de patiënten een BNP 
waarde < 100 pg/ml gevonden. Wij onderzochten de prevalentie van stabiele patiënten die 
vlak voor ontslag uit het ziekenhuis na een opname voor hartfalen een BNP < 100 pg/ml 
hadden. In hoofdstuk 7 hebben we laten zien dat slechts 10% van deze populatie een BNP 
waarde < 100 pg/ml had. Deze patiënten met lage BNP waarden hadden minder ernstig 
hartfalen en vaker een behouden systolische functie vergeleken met patiënten met BNP 
waarden ≥ 100 pg/ml.
In de discussie (hoofdstuk 8) beschreven we dat het aan de ene kant wenselijk lijkt om 
verschillende afkapwaarden voor BNP en NT-proBNP te gebruiken in verschillende popu-
laties, aangezien natriuretische peptiden niet alleen door de ernst van het hartfalen worden 
beïnvloed, maar ook door diverse andere factoren, zoals leeftijd, nierfunctie en anemie (dit 
proefschrift). In de praktijk is het echter erg onpraktisch om verschillende afkapwaarden te 
gebruiken voor de verschillende patiëntengroepen. Dit betekent dat elke BNP of NT-proBNP 
waarde geïnterpreteerd zou moeten worden rekening houdend met de ernst van hartfalen 
en alle andere beïnvloedende factoren. Verder kwam in de discussie de keuze voor het ge-
bruik van BNP of NT-proBNP aan de orde en bespraken we in welke klinische situaties BNP 
en NT-proBNP kunnen worden gebruikt. Tenslotte hebben we verscheidene aanbevelingen 
gedaan voor toekomstig klinisch toegepast onderzoek over BNP en NT-proBNP bij patiën-
ten met hartfalen. 
Concluderend hebben BNP en NT-proBNP belangrijke voordelen in de behandeling van 122
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patiënten met mogelijk of vastgesteld hartfalen, inclusief, zoals beschreven in dit proefschrift, 
de patiënten die op het punt staan te worden ontslagen na opname voor verdenking op hart-
falen. Naast de voordelen hebben onze studies echter ook belangrijke beperkingen van het 
gebruik van BNP en NT-proBNP laten zien, die meegenomen moeten worden bij het besluit 
of BNP of NT-proBNP waarden bepaald moeten worden. Tevens moeten deze beperkingen 
in overweging worden genomen bij de interpretatie van de test resultaten. Dankwoord126
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Tijdens de afgelopen jaren zijn veel waardevolle mensen op mijn pad gekomen die mij, 
ieder op zijn eigen wijze, hebben ondersteund in het welslagen van mijn onderzoek. Ik wil 
een aantal van deze mensen graag persoonlijk bedanken. 
Allereerst ben ik erg blij met de inzet van de honderden patiënten die hebben deelgenomen 
aan de COACH studie. Zonder alle ingevulde vragenlijsten, afgegeven buisjes bloed en extra 
visites aan het ziekenhuis had dit proefschrift er nu niet gelegen. Ook wil ik de Nederlandse 
Hartstichting hartelijk bedanken voor het mogelijk maken van de COACH studie. 
Dr. T. Jaarsma, mijn eerste copromotor. Beste Tiny, ik ben je dankbaar dat je me als jonge 
hond vol vertrouwen in het COACH team hebt opgenomen. Je hebt me met veel betrok-
kenheid begeleid en jouw strategische inzicht, kritische vragen (‘Waarom willen we dat 
weten?’) en enthousiasme heb ik zeer gewaardeerd. Ook heb je me veel mogelijkheden 
geboden om mezelf te ontwikkelen (cursussen en congressen) en je jaarlijkse prikkelende 
Sinterklaas gedichten waren erg motiverend . 
Mijn eerste promotor Prof. dr. D.J. van Veldhuisen. Beste Dirk Jan, bedankt voor je gedreven-
heid en onophoudelijk enthousiasme voor mijn vorderingen in de afgelopen jaren. Jouw 
‘motto’ om per artikel steeds één eenvoudige boodschap te verkondigen en deze helder en 
krachtig te formuleren is duidelijk terug te vinden in dit proefschrift. 
Mijn tweede promotor Prof. dr. A.W. Hoes. Beste Arno, tijdens de overlegmomenten die we 
hebben gehad heb ik je bijdrage altijd erg gewaardeerd; je luisterde, dacht mee en leverde 
zeer constructieve bijdrages. Jouw aandacht voor de kwaliteit en klinische relevantie van 
wetenschappelijk onderzoek heeft mij sterk geïnspireerd om in de toekomst verder te gaan 
met toegepast (klinisch-) wetenschappelijk onderzoek.
Mijn tweede copromotor Dr. A.A. Voors. Beste Adriaan, bedankt voor je inzet (o.a. voor het 
beoordelen van de ‘mappen’), directe beschikbaarheid en feedback die je me hebt gegeven. 
Jouw cardiologische blik was erg belangrijk voor de vertaalslag van onze onderzoeksresul-
taten naar klinische toepassingsgebieden. 
Mijn paranimfen. Beste Martje en Marie Louise, ik wil jullie hartelijk bedanken voor de 
steun en adviezen tijdens ups en downs in de hele periode van mijn promotieonderzoek, 
maar ook en in het bijzonder gedurende de laatste maanden voor mijn verdediging. De 
manier waarop jullie het paranimfschap hebben ingevuld en de wijze waarop jullie me 
hebben geholpen bij alle perikelen heb ik erg gewaardeerd. Ik ben erg blij dat jullie mijn 
paranimfen hebben willen zijn! 
Ivonne Lesman. Beste Ivonne, dank je voor je steun en interesse in mijn ontwikkelingen in 
de afgelopen jaren. Ik was blij dat je erbij was tijdens het paspoort incident aan de grens 
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en Prof. dr. J.G.P. Tijssen, dank voor het kritisch beoordelen van mijn proefschrift.
Dr. H. L. Hillege. Beste Hans, je was intensief betrokken bij mijn artikelen en leverde altijd 
goede adviezen voor de statistische analyses.
Het Trial Coördinatie Centrum (TCC). Beste Nic, Diane, Marco, Janneke, Roos, Anne Rixt, 
Carla, Olga, Ilse en Rob; dankzij jullie inzet en begeleiding (het scannen van de vragenlijsten, 
monitoring van de data) is COACH onder meer succesvol volbracht.
Laboratorium medewerkers. 
Dr. F. Boomsma, Beste Frans, tijdens onze gezellige afspraken in het begin van mijn promo-
tietraject, heb je me ingewijd in de wereld van natriuretische peptiden en heb je benadrukt 
dat er meer is dan werk en dat ik ook vooral moest genieten van het leven, dank daarvoor. 
Prof. dr. F.A.J. Muskiet, Drs. H. Breukelman en dhr. J. Pietens hartelijk bedankt voor de on-
dersteuning en de geboden mogelijkheden in het kader van laboratorium bepalingen voor 
de COACH studie. 
Jan Koerts. Beste Jan, ik wil je bedanken voor de analyserondes van (NT-pro)BNP en de 
randvoorwaarden daarvoor die je hebt georganiseerd. Alles was bijna mogelijk; zelfs toen ik 
’s avonds laat terug kwam van een ronde door Nederland voor het ophalen van bloedmon-
sters op droogijs stond je paraat om de monsters in ontvangst te nemen. 
Eduard Heine en Detta van der Molen. Beste Eduard en Detta, bedankt voor de bepalingen 
van (NT-pro)BNP in de vele bloedmonsters die er binnen de COACH studie zijn verza-
meld. 
De secretaresses van de Cardiologie. Beste Alma, Audrey en Olga, hartelijk bedankt voor 
jullie ondersteuning tijdens met name de hectische eindperiode van mijn onderzoek. Jullie 
planning- en organisatiekwaliteiten heb ik zeer gewaardeerd!
Dr. M.J.L. de Jongste. Beste Mike, jouw bijdrage aan ons ‘outcome panel’ en je beoordelin-
gen van de ‘mappen’ waren van grote waarde. 
Roel Meijer. Beste Roel, Ik wil je hartelijk bedanken voor het mooie ontwerp voor de om-
slag van dit proefschrift. Ik ben er erg blij mee!
Cardio research. Beste Anja, Peter, Trienke, Greetje, Zaza en Margriet, bedankt voor de inte-
resse en voor het gebruik van jullie monitor kamertje om in de laatste fase van mijn traject 
ongestoord te kunnen schrijven. 
De researchassistenten. Beste Meint, Wim, Peter en Tom bedankt voor de interesse en gezel-
ligheid gedurende de afgelopen jaren. 
Mijn familie en schoonfamilie. Papa en mama, hartelijk bedankt voor jullie onvoorwaar-
delijke steun en betrokkenheid tijdens mijn promotieonderzoek. Sanne, Linde en Machiel, 
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ook jullie interesse in -en directe medewerking aan mijn project (vele interviews!) heeft 
mij erg goed gedaan. Albert, Marian, Dolf en Paulien, ik wil jullie bedanken voor jullie 
interesse en ondersteuning.
De ‘Bruine beren’. Beste Rolf, Marc, Luc, Martijn en Raph, jullie afleiding en de steun in 
moeilijke tijden was belangrijk voor mij. De vele rondjes hardlopen en gezellige etentjes 
gaven mij veel energie. Tijdens de ‘bruine beren tochten’ waren de ‘summits’ vaak (licha-
melijk) zwaar, maar daardoor smaakte de boerenkool gekookt met gesmolten sneeuw extra 
goed. Tijdens deze tochten kon ik mijn zinnen even verzetten.
Sport vrienden. Beste Matthijs, Chris en Remy, jullie betrokkenheid, gezelligheid en onze 
rondjes over o.a. de Utrechtse Heuvelrug en de Marmotte op de racefiets met het bijbeho-
rende bijpraten, hebben me in staat gesteld om me geestelijk te ontspannen via lichamelijke 
inspanning! 
Marijn de Bruin. Beste Marijn, dank je voor de betrokkenheid, de gezellige avondjes en 
goede gesprekken.
Lieve Marijn, ik wil je bedanken voor je geduld, voor je luisterend oor en voor je advies 
tijdens alle perikelen rond artikelen. Ik ben blij dat je het belang van promotieonderzoek 
steeds hebt gerelativeerd (‘het is belangrijk dat je het werk leuk vindt, niet dat je straks dr. 
bent’) en ik wil je bedanken voor de fijne en ontspannende weekenden die we samen in 
Maastricht en in Utrecht hebben doorgebracht. 
Dankwoord129
Dankwoord NHS-COACH betrokkenen
De COACH studie is uitgevoerd in 17 ziekenhuizen in Nederland. Zonder de grote inzet 
van vele cardiologen, hartfalenverpleegkundigen, dataverzamelaars en laboratorium me-
dewerkers had dit proefschrift er nu niet gelegen. Ik wil deze mensen dan ook hartelijk 
bedanken: 
Universitair Medisch Centrum Groningen 
Cardiologen: Prof. dr. D. J. van Veldhuisen, Dr. A.A. Voors 
Hartfalenverpleegkundigen: Drs. A. Koops, Mevr. A. Klungel, Mevr. K van Dijk, Dhr. G. 
Westra.
Dataverzamelaars: Mevr. G. Feringa, Mevr. A. Schwencke, Mevr. L. Grevink, Mevr. K. 
Bruggink 
Laboratorium: Drs. H. Breukelman, Dhr. J. Pietens, Dhr. J. Koerts, Mevr. D. van der Molen, 
Dhr. E. Heine
Academisch Medisch Centrum, Amsterdam 
Cardiologen/artsen Prof. dr. J.G.P. Tijssen, Dr. W. Kok, Dr. L.M. Konst, Dr. J. van der Sloot. 
Hartfalenverpleegkundigen: Mevr. T. Veelenturf, Dhr. R. Zwart, Mevr. S. de Vries
Dataverzamelaars: Mevr. L. IJzerman, Dhr. R. Zuidervaart, Mevr. E. Spoelstra, Mevr. S. Stul-
tiëns
Laboratorium: Mevr. W. van Lüling
Universitair Medisch Centrum St. Radboud, Nijmegen 
Cardiologen: Prof. dr. F. Verheugt, Drs. L. Bellersen. 
Hartfalenverpleegkundigen: Dhr. L. Knubben, Mevr. L. Baltussen 
Dataverzamelaars: Mevr. J. de Natris, Drs. L. Hogenhuis
Laboratorium: Dhr. J. Verhagen
Medisch Centrum Leeuwarden 
Cardiologen: Drs. C.J. de Vries, Drs. R. Breedveld 
Hartfalenverpleegkundigen: Mevr. A. Obbema, Mevr. A. Rijenga, Mevr. D. van der Woude, 
Mevr. J. de Bruin 
Dataverzamelaars: Mevr. A. Jonkman, Mevr. C. Wassenaar
Laboratorium: Mevr. A. Weiland
Twenteborg Ziekenhuis, Almelo 130
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Cardioloog: Drs. G.C.M Linssen 
Hartfalenverpleegkundigen: Mevr. E. Rodijk, Mevr. M. Samsen, Mevr. B. Beverdam, 
Mevr. L. Bogemann 
Dataverzamelaars: Mevr. H. Hondebrink, Mevr. A. Disberg, Mevr. M. Slaghekke
Laboratorium: Dhr. J. Sanderman
Atrium Medisch Centrum, Heerlen 
Cardioloog: Dr. J.A. Kragten 
Hartfalenverpleegkundigen: Dhr. T. Thuis, Mevr. I. Kremer, Mevr. V. Post, Mevr. S. Jongen
Dataverzamelaars: Drs. S. Hogenhuis, Drs. E. Gaasbeek, Drs. C. Beumer, Mevr. B. Hoen
Laboratorium: Mevr. H. de Waal, Dr. R. Baumgarten.
Jeroen Bosch Ziekenhuis, Den Bosch 
Cardioloog: Dr. M.C.G. Daniëls 
Hartfalenverpleegkundigen: Dhr. D. Jaftoran, Dhr. V. van Zonsbeek, Mevr. A. Berkhout 
Dataverzamelaars: Mevr. I. Samshuizen, Mevr. D. Oosterkerk
Laboratorium: Dhr. M. Paanakker
Rijnstate Ziekenhuis, Arnhem 
Cardioloog: Dr. F.F. Willems 
Hartfalenverpleegkundigen: Drs. M. Rolfes, Mevr. P. Nienaber
Dataverzamelaars: Mevr. J. de Natris, Mevr. M. Hubertus, Drs. L. Hogenhuis, 
Mevr. E. Eleveld
Laboratorium: Dhr. K. Quartz, Mevr. M. Mekking
Streekziekenhuis Midden Twente, Hengelo 
Cardioloog: Drs. A. Derks 
Hartfalenverpleegkundigen: Mevr. L. Odink, Mevr. P. ter Horst, Mevr. W. Wolters, 
Mevr. L. Navis 
Dataverzamelaars: Mevr. J. Bijen, Mevr. I. Horstman, Mevr. A. Ottenhof, Mevr. W. Bakker, 
Mevr. B. Nijhuis
Laboratorium: Mevr. K. Vlaskamp
Refaja Ziekenhuis, Stadskanaal 
Cardioloog: Dr. L. van Wijk, Dr. K. de Vries 
Hartfalenverpleegkundigen: Mevr. D. Thoma, Mevr. R. Niewold, Mevr. M. Wijbenga
Dataverzamelaars: Mevr. S. Vennik, Drs. E. Prins
Laboratorium: Dhr. G. Edinga, Dhr. H. Bakker
Tweesteden Ziekenhuis, Tilburg 
Cardioloog: Dr. J. Widdershoven 
Hartfalenverpleegkundigen: Dhr. E. Hendriks, Dhr. H. Broers 
Dataverzamelaars: Dhr. K. Jansen, Mevr. B. de Kruijf, Mevr. K. de Beer
Laboratorium: Dhr. H. Loonen.
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Amphia Ziekenhuis, Breda 
Cardioloog: Dr. P.H.J.M. Dunselman 
Hartfalenverpleegkundigen: Mevr. N. Creemer, Mevr. I. de Regt 
Dataverzamelaars: Mevr. J. Hendriks, Mevr. A. Lotstra, Dhr. K. Terlaak
Laboratorium: Mevr. M. Adriaanse
 
Deventer Ziekenhuizen, Deventer
Cardioloog: Drs. D.J.A. Lok 
Hartfalenverpleegkundigen: Dhr. J. Burger, Mevr. D. Pruijsers 
Dataverzamelaars: Mevr. L. Schoterman, Mevr. M. van Buijsen, Mevr. M. Scholten, 
Dhr. H. Verheij
Laboratorium: Dhr. H. Salden.
 
Wilhelmina Ziekenhuis, Assen
Cardioloog: Dr. M.L. Pentinga 
Hartfalenverpleegkundigen: Mevr. R. Aardema, Mevr. J. Veninga 
Dataverzamelaars: Mevr. E. Tiemes, Mevr. E. de Vos, Mevr. N. van der Linden, Mevr. E. Voois
Laboratorium: Dhr. J. Vulperhorst
Scheper Ziekenhuis, Emmen 
Cardioloog: Dr. M.J. Nagelsmit 
Hartfalenverpleegkundigen: Mevr. A. Bakker, Dhr. W. Veenstra, Dhr J.W. van Brakel 
Dataverzamelaars: Mevr. J. Kruimink, Mevr. J. Pool, Mevr. R. de Heus
Laboratorium: Dhr. R. van Putten
Medisch Spectrum Twente, Enschede 
Cardioloog: Dr. Ph. van der Burgh 
Hartfalenverpleegkundigen: Mevr. J. Roukema, Mevr. H. Glazenburg, Mevr. J. Grooters 
Dataverzamelaars: Mevr. T. Meijer, Mevr. H. Vroom, Mevr. J. Poggenklas
Laboratorium: Mevr. R. Kienhuis, Mevr. C. Kasper
Oosterschelde Ziekenhuis, Goes 
Cardioloog: Dr. A.H. Liem 
Hartfalenverpleegkundigen: Mevr. J. Witkam, Mevr. A. Roelse, Mevr. E. Salawanei 
Dataverzamelaars: Mevr. A. Remijn, Mevr. M. Franse, Mevr. E. Wijs
Laboratorium: Dhr. B. Speckens
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